Photodynamic Therapy and Diagnostics
Patent Information
- Application Number
- JP2023532650
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-26
- Filing Date
- 2021-11-26
- Publication Date
- 2024-12-04
AI Technical Summary
There is a need for photosensitizers with high singlet oxygen quantum yields, strong photosensitivity in organic and aqueous media, high fluorescence quantum yields, lower dark toxicity, better stability, and ease of purification for photodynamic therapy applications.
Development of phyllochlorin analogs and their pharmaceutically acceptable salts, specifically compounds of formula (I) or complexes of formula (II), which include various functional groups and metal ions, providing improved phototoxicity and stability.
The phyllochlorin analogs exhibit enhanced photodynamic therapy efficacy with improved phototoxicity, stability, and ease of purification, making them suitable for treating tumors and antiviral therapies.
Smart Images

Figure 2022112537000001 
Figure 2022112537000002 
Figure 2022112537000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to phyllochlorin analogues and pharmaceutically acceptable salts thereof, as well as compositions comprising phyllochlorin analogues and pharmaceutically acceptable salts thereof. Phyllochlorin analogues and pharmaceutically acceptable salts thereof are suitable for use in photodynamic therapy, cytoluminescence therapy and photodynamic diagnosis, for example, in the treatment or detection of tumors or in antiviral therapy. The present invention also relates to the use of phyllochlorin analogues and pharmaceutically acceptable salts thereof in the manufacture of phototherapeutic or photodiagnostic agents, as well as methods for photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis, for example, in the treatment or detection of tumors or in antiviral therapy.
[0002] The structure of "phyllochlorin" is as follows: [ka] [Background technology]
[0003] Porphyrins and their analogues are known photosensitive chemical compounds that can absorb photons and emit them at higher wavelengths. These unique properties have many applications, one of which is photodynamic therapy (PDT). There are currently two generations of photosensitizers for PDT: the first generation contains heme porphyrins (blood derivatives), and the second generation is mostly chlorophyll analogues, the latter compounds known as chlorins and bacteriochlorins.
[0004] Chlorin e4 has been shown to exhibit good photosensitizing activity. It has also been shown to have protective effects against indomethacin-induced gastric lesions in rats and TAA- or CCl4-induced acute liver injury in mice. Therefore, it has been suggested that chlorin e4 may be a promising new drug candidate for anti-gastroenteritis and liver damage protection. WO2009 / 040411 suggests the use of chlorin e4 zinc complexes in photodynamic therapy, and WO2014 / 091241 suggests the use of chlorin e4 disodium in photodynamic therapy. [ka]
[0005] However, there is a continuing need for better photosensitizers. There is a need for compounds with high singlet oxygen quantum yields, and preferably compounds with strong photosensitizing properties in organic and aqueous media. There is also a need for compounds with high fluorescence quantum yields. Furthermore, there is a need for compounds and / or compositions that have higher phototoxicity, lower dark toxicity, good stability, and / or are easily purified. Summary of the Invention
[0006] A first aspect of the present invention is a compound of formula (I) or a complex of formula (II), [ka] During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 3 are independently -H, -R α -H, -R β , -R α -Rβ , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 6 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, wherein the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene groups can be optionally replaced with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or contain a cyclic group which may be optionally substituted and which may optionally include one or more heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n-CH3, phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 6 optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counterion; X is a halo group; M 2+ is a metal ion; providing a compound of formula (I) or a complex of formula (II), or a pharmaceutically acceptable salt thereof; However, the compound is (1) phyllochlorin free acid; or (2) Provided that it is not phyllochlorin methyl ester.
[0007] The structure of phyllochlorin free acid is: [ka]
[0008] The structure of phyllochlorin methyl ester is: [ka]
[0009] A second aspect of the present invention is a compound of formula (I) or a complex of formula (II) [ka] During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 3 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 6 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, wherein the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene groups can be optionally replaced with one or more heteroatoms O or S; -R βare each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or contain a cyclic group which may be optionally substituted and which may optionally include one or more heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 6 optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counterion; X is a halo group; M 2+ is a metal ion; a compound of formula (I) or a complex of formula (II), or a pharmaceutically acceptable salt thereof, Provided for use in medicine.
[0010] In some embodiments of the second aspect of the invention, the compound is (1) phyllochlorin free acid; or (2) Phyllochlorin methyl ester.
[0011] In the context of this specification, a "hydrocarbyl" substituent or hydrocarbyl moiety in a substituent contains only carbon and hydrogen atoms, but does not include any heteroatoms such as N, O, S, P, or Se in its carbon skeleton, unless otherwise specified. Hydrocarbyl groups / moieties can be saturated or unsaturated (including aromatic), straight or branched chain, or can be or include cyclic groups, and unless otherwise specified, cyclic groups do not include heteroatoms such as N, O, S, P, or Se in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl groups / moieties, and all combinations of these groups / moieties. Typically, hydrocarbyl groups are C1-C 60 Hydrocarbyl groups, more typically C1-C 40 Hydrocarbyl groups, more typically C1-C 20 More typically, the hydrocarbyl group is a C1-C 12 More typically, the hydrocarbyl group is a C1-C 10 A "hydrocarbylene" group is defined as a divalent hydrocarbyl group.
[0012] An "alkyl" substituent or alkyl moiety in a substituent can be linear (i.e., straight-chain) or branched. Examples of alkyl groups / moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and n-pentyl groups / moieties. Unless otherwise specified, the term "alkyl" does not include "cycloalkyl." Typically, alkyl groups are C1-C6 12 It is an alkyl group. More typically, the alkyl group is a C1-C6 alkyl group. An "alkylene" group is defined similarly as a divalent alkyl group.
[0013] An "alkenyl" substituent or alkenyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and 1,4-hexadienyl groups / moieties. Unless otherwise specified, the term "alkenyl" does not include "cycloalkenyl." Typically, alkenyl groups are C2-C6 12 It is an alkenyl group. More typically, the alkenyl group is a C2-C6 alkenyl group. An "alkenylene" group is defined similarly as a divalent alkenyl group.
[0014] An "alkynyl" substituent or alkynyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-1-ynyl, and but-2-ynyl. Typically, alkynyl groups are C2-C 12 It is an alkynyl group. More typically, the alkynyl group is a C2-C6 alkynyl group. An "alkynylene" group is defined similarly as a divalent alkynyl group.
[0015] A "cyclic" substituent or cyclic moiety in a substituent refers to any hydrocarbyl ring, which may be saturated or unsaturated (including aromatic) and may contain one or more heteroatoms, such as N, O, S, P, or Se, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl, and heteroaryl groups, discussed below. Cyclic groups may be monocyclic, bicyclic (e.g., bridged, fused, or spiro), or polycyclic. Typically, cyclic groups are 3- to 12-membered cyclic groups, meaning they contain 3 to 12 ring atoms. More typically, cyclic groups are 3- to 7-membered monocyclic groups, meaning they contain 3 to 7 ring atoms.
[0016] A "heterocyclic" substituent or heterocyclic moiety in a substituent refers to a cyclic group or moiety that includes one or more carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, such as N, O, S, P, or Se, in the ring structure. Examples of heterocyclic groups include the heteroaryl groups discussed below, as well as non-aromatic heterocyclic groups such as azetidinyl, azetinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, thietanyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, thianyl, and dioxanyl groups.
[0017] A "cycloalkyl" substituent or cycloalkyl moiety in a substituent refers to a saturated hydrocarbyl ring containing, for example, 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, a cycloalkyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0018] A "cycloalkenyl" substituent or cycloalkenyl moiety in a substituent refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, and cyclohexa-1,3-dien-1-yl. Unless otherwise specified, a cycloalkenyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0019] An "aryl" substituent or aryl moiety in a substituent refers to an aromatic hydrocarbyl ring. The term "aryl" includes monocyclic aromatic hydrocarbons and polycyclic fused-ring aromatic hydrocarbons, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl, and phenanthrenyl. Unless otherwise specified, the term "aryl" does not include "heteroaryl."
[0020] A "heteroaryl" substituent or heteroaryl moiety in a substituent refers to an aromatic heterocyclic group or moiety. The term "heteroaryl" includes monocyclic aromatic heterocycles and polycyclic fused-ring aromatic heterocycles, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of heteroaryl groups / moieties include: [ka] where G=O, S or NH.
[0021] For purposes of this specification, when a combination of moieties is referred to as a group, e.g., arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl, the last-mentioned moiety includes the atoms of the remainder of the molecule to which the group is attached. An example of an arylalkyl group is benzyl.
[0022] For purposes of this specification, an optionally substituted group or moiety (-R β etc.), (i) each hydrogen atom is optionally replaced by halo; -CN; -NO; -N; -R x ;-OH;-OR x ;-R y -Haro;-R y -CN;-R y -NO2;-R y -N3;-R y -R x ;-R y -OH;-R y -OR x ;-SH;-SR x ;-SOR x ;-SO2H;-SO2R x ;-SO2NH2;-SO2NHR x ;-SO2N(R x )2;-R y -SH;-R y -SR x ;-R y -SORx ;-R y -SO2H;-R y -SO2R x ;-R y -SO2NH2;-R y -SO2NHR x ;-R y -SO2N(R x )2;-NH2;-NHR x ;-N(R x )2;-N + (R x )3;-R y -NH2;-R y -NHR x ;-R y -N(R x )2;-R y -N + (R x )3;-CHO;-COR x ;-COOH;-COOR x ;-OCOR x ;-R y -CHO;-R y -COR x ;-R y -COOH;-R y -COOR x or -R y -OCOR x and / or may be substituted with monovalent substituents independently selected from (ii) Any two hydrogen atoms attached to the same carbon atom are oxo (=O), =S, =NH, or =NR x and / or (iii) Any two hydrogen atoms bonded to the same or different atoms within the same optionally substituted group or moiety may be replaced by —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -, and optionally substituted with a bridging substituent independently selected from where each -R y- is independently selected from an alkylene, alkenylene, or alkynylene group which contains 1 to 6 atoms in its backbone; one or more carbon atoms in the backbone of an alkylene, alkenylene, or alkynylene group can optionally be replaced with one or more heteroatoms N, O, or S; and the alkylene, alkenylene, or alkynylene group can optionally contain one or more halo and / or -R x groups; and Each-R x are independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C2-C6 cyclic groups, or any two or three -R attached to the same nitrogen atom x may form a C2-C7 cyclic group together with the nitrogen atom to which they are attached, and any -R x can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), halo, —OH, —NH2, —CN, or oxo (═O) groups.
[0023] Typically, the substituents include 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, more typically 1 substituent.
[0024] Unless otherwise specified, any divalent bridging substituent (e.g., —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -) or moiety must be attached only to the specified group or moiety and cannot be attached to a second group or moiety, even if the second group or moiety itself may be optionally substituted.
[0025] The term "halo" includes fluoro, chloro, bromo and iodo.
[0026] Unless otherwise specified, when a group is prefixed with the term "halo," such as a haloalkyl or halomethyl group, it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two, or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four, or five halo substituents. Similarly, unless otherwise specified, when a group begins with a particular halo group, it is understood that the group in question is substituted with one or more of the specified halo groups. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two, or three fluoro groups.
[0027] Unless otherwise specified, when a group is referred to as "halo-substituted," it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the group referred to as halo-substituted. For example, a halo-substituted methyl group may contain one, two, or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four, or five halo substituents.
[0028] Unless otherwise specified, a reference to an element is considered to be a reference to all isotopes of that element, so for example, unless otherwise specified, a reference to hydrogen is considered to encompass all isotopes of hydrogen, including deuterium and tritium.
[0029] Unless otherwise stated, a reference to a compound or group should be understood to refer to all tautomeric forms of that compound or group.
[0030] When referring to a hydrocarbyl or other group that contains one or more heteroatoms N, O, S, P or Se in its carbon skeleton, or to a carbon atom of a hydrocarbyl or other group that is substituted by an N, O, S, P or Se atom, what is intended is: [ka] is replaced by; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; -CH3 is replaced by -NH2, -PH2, -OH, -SH, or -SeH; -CH= is replaced by -N= or -P=; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; or CH≡ is replaced by N≡ or P≡; provided that the resulting group contains at least one carbon atom. For example, methoxy, dimethylamino, and aminoethyl groups are considered to be hydrocarbyl groups containing one or more heteroatoms N, O, S, P, or Se in their carbon skeleton.
[0031] In the context of this specification, unless otherwise stated, C x ~C y A group is defined as a group containing x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing 1 to 4 carbon atoms. When calculating the total number of carbon atoms in a parent group, including any substituted and / or moieties, optional substituents and moieties are not taken into account. For the avoidance of doubt, substituted heteroatoms, e.g., N, O, S, P, or Se, are not included in the C x ~C y When calculating the number of carbon atoms in a group, they should be counted as carbon atoms. For example, a morpholinyl group should be considered a C6 heterocyclic group, not a C4 heterocyclic group.
[0032] Because the pi electrons of the chlorin ring are delocalized, the chlorin ring can be represented by multiple resonance structures. Resonance structures are different ways of depicting the same compound. Two of the resonance structures for the chlorin ring are shown directly below. [ka]
[0033] Typically, a complex contains a central metal atom or ion, known as the coordination center, and binding molecules or ions, known as ligands. Herein, the bond between the coordination center and the ligands is represented as shown in the complex at the bottom left (the attraction between the anionic ligand and the central metal cation is represented by four dashed lines), but equivalently, it is represented as shown in the complex at the bottom right (the attraction between the ligand molecules and the central metal atom is represented by two covalent bonds and two dashed lines). [ka]
[0034] In the present context, the term "phyllochlorin analogues" encompasses compounds of the invention comprising the phyllochlorin free acid according to the second aspect of the invention.
[0035] As used herein, -[NC5H5]Y means [ka] Refers to...
[0036] In one embodiment of the first or second aspect of the invention, Y is a counterion selected from a halide (e.g., fluoride, chloride, bromide, or iodide) or other inorganic anion (e.g., nitrate, perchlorate, sulfate, bisulfate, or phosphate) or an organic anion (e.g., propanoate, butyrate, glycolate, lactate, mandelate, citrate, acetate, benzoate, salicylate, succinate, malate, tartrate, fumarate, maleate, hydroxymaleate, galactarate, gluconate, pantothenate, pamoate, methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, toluene-p-sulfonate, naphthalene-2-sulfonate, camphorsulfonate, ornithine, glutamate, or aspartate). In one embodiment, Y is fluoride, chloride, bromide or iodide. In one embodiment, Y is chloride or bromide.
[0037] In one embodiment of the first or second aspect of the invention, X is a halo group selected from fluoro, chloro, bromo, or iodo. In one embodiment, X is chloro or bromo.
[0038] In one embodiment of the first or second aspect of the invention, M 2+ Zn 2+ , Cu 2+ , Fe 2+ , Pd 2+ or Pt 2+ In one embodiment, M 2+ is Zn 2+ is.
[0039] In one embodiment of the first or second aspect of the present invention, there is provided a compound of formula (I):
[0040] -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3, -C(S)-SR 3 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2 is selected.
[0041] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R βis a saccharidiyl group. In one embodiment, -R 1 is -C(O)-OR 3 or -C(O)-SR 3 -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group. Typically, in these embodiments, -R α - is C1~C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.
[0042] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -OR β , -R α -SR β , -R α-S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.
[0043] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 -R refers to the group 3 and -R 3’ may be the same or different. Preferably, -R 3 and -R 3’ is different.
[0044] In one embodiment of the first and second aspects of the present invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -R βor -R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -R β or -R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.
[0045] In any of the embodiments of the previous four paragraphs, the saccharidiyl group may optionally be substituted, for example, with a protecting group such as acetyl or a natural amino acid such as valine. The amino acid may be attached to the saccharidiyl group, for example, by forming an ester between the carboxylic acid group of the amino acid and the hydroxyl group of the saccharidiyl group.
[0046] In one embodiment of the first and second aspects of the present invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -R β or -R β -R βis a C1-C8 alkylene group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -R β or -R β -R β is a C1-C8 alkylene group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is an unsubstituted C1 to C6 alkylene group, or an unsubstituted C1 to C4 alkylene group, or an unsubstituted C1 to C2 alkylene group.
[0047] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) and -R 3 -R α -H or -R α -OH, -R α - is C1~C 12 alkylene groups, where the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally replaced with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R3’ ) where -R 3 -R α -H or -R α -OH, -R α - is C1~C 12 alkylene groups, wherein one or more carbon atoms in the backbone of the alkylene group can be optionally replaced by one or more heteroatoms O or S; 3’ is H or C1-C4 alkyl (preferably methyl).
[0048] In one embodiment of the first and second aspects of the present invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 Ha-R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents selected from —NH2 12 is an alkyl group, and each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R 3’is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z -NH2, wherein each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl).
[0049] In one embodiment of the first and second aspects of the present invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 Ha-R α -[P(R 5 )3]Y, and each -R 5is independently selected from phenyl or C5-C6 heteroaryl, and phenyl or C5-C6 heteroaryl optionally includes one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CHO) n -H or -O-(CH2CH2O) n -CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -[P(R 5 )3]Y, and each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, and the phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CHO) n -H or -O-(CH2CH2O) n -CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.
[0050] In one embodiment of the first or second aspect of the invention, -R 1 -C(O)-OR 3 where -R 3is selected from C1-C4 alkyl (preferably methyl), or cations (such as lithium, sodium, potassium, magnesium, calcium, ammonium, amine (such as choline or meglumine) or amino acid (such as arginine) cations).
[0051] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 )
[0052] In one embodiment of the first or second aspect of the invention, each -R α - are independently C1 to C 12 Alkylene group, -(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - are independently C1 to C 12 Alkylene group or -(CH2CH2O) m - groups, both of which are optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - is independently an optionally substituted -(CH2CH2O) m - group, where m is 1, 2, 3 or 4.
[0053] In one embodiment of the first or second aspect of the invention, each -Rα - is independently a C1-C8 alkylene group, or a C1-C6 alkylene group, or a C2-C4 alkylene group, all optionally substituted.
[0054] In one embodiment of the first or second aspect of the invention, each -R α - is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α - is independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α - is unsubstituted.
[0055] In one embodiment of the first and second aspects of the invention, each -R β are independently saturated or unsaturated hydrocarbyl groups which may be linear or branched or which may be or include cyclic groups, which may be optionally substituted, and which may optionally include one or more heteroatoms N, O or S in its carbon skeleton.
[0056] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all of which are optionally substituted. β are independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all optionally substituted.
[0057] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a saccharidiyl group. In one embodiment, each -R β are independently a saccharidiyl group.
[0058] In one embodiment of the first or second aspect of the invention, each -R β is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. β is independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R β is non-substituted.
[0059] In one embodiment of the first and second aspects of the invention, each -R 3 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 3independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β -R β is a saccharidiyl group.
[0060] In one embodiment of the first and second aspects of the present invention, at least one -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, at least one -R 3 independently, -R α -OR β or -R α -SR β -R β is a saccharidiyl group.
[0061] For purposes of the present invention, a "saccharidiyl group" is any group comprising at least one monosaccharide subunit, each of which may be optionally substituted and / or modified. Typically, a saccharidiyl group is composed of one or more monosaccharide subunits, each of which may be optionally substituted and / or modified.
[0062] Usually, the carbon atom of a single monosaccharide subunit of each saccharidiyl group is directly attached to the remainder of the compound, most typically via a single bond.
[0063] For purposes of this specification, when a first atom or group is said to be "directly bonded" to a second atom or group, it is to be understood that the first atom or group is covalently bonded to the second atom or group and that there are no intervening atom(s) or group(s). For example, in the group -(C=O)N(CH), the carbon atom of each methyl group is directly bonded to the nitrogen atom and the carbon atom of the carbonyl group is directly bonded to the nitrogen atom, but the carbon atom of the carbonyl group is not directly bonded to the carbon atoms of either methyl group.
[0064] Typically, each saccharidiyl group is derived from the corresponding saccharide by replacing a hydroxyl group of the saccharide with a group defined by the remainder of the compound.
[0065] The single bond between the anomeric carbon of a monosaccharide subunit and a substituent is called a glycosidic bond. A glycosidic group is attached to the anomeric carbon of a monosaccharide subunit by a glycosidic bond. The bond between the saccharidiyl group and the rest of the compound can be a glycosidic or non-glycosidic bond. Typically, the bond between the saccharidiyl group and the rest of the compound is a glycosidic bond, and the saccharidiyl group is a glycosyl group. When the bond between the saccharidiyl group and the rest of the compound is a glycosidic bond, the glycosidic bond can be in the α or β configuration. Typically, such glycosidic bond is in the β configuration.
[0066] For the purposes of the present invention, when a saccharidiyl group "contains x monosaccharide subunits," this means that the saccharidiyl group has x monosaccharide subunits and no more. In contrast, when a saccharidiyl group "comprises x monosaccharide subunits," this means that the saccharidiyl group has x or more monosaccharide subunits.
[0067] Each saccharidiyl group can be independently selected from a monosaccharidiyl, disaccharidiyl, oligosaccharidiyl, or polysaccharidiyl group. As will be understood, a monosaccharidiyl group contains a single monosaccharide subunit. Similarly, a disaccharidiyl group contains two monosaccharide subunits. As used herein, an "oligosaccharidiyl group" contains 2 to 9 monosaccharide subunits. Examples of oligosaccharidiyl groups include trisaccharidiyl, tetrasaccharidiyl, pentasaccharidiyl, hexasaccharidiyl, heptasaccharidiyl, octasaccharidiyl, and nonasaccharidiyl groups. As used herein, a "polysaccharidiyl group" contains 10 or more monosaccharide subunits (such as 10 to 50, or 10 to 30, or 10 to 20, or 10 to 15 monosaccharide subunits).
[0068] Each monosaccharide subunit within a disaccharidediyl, oligosaccharidediyl, or polysaccharidediyl group can be the same or different. Each monosaccharide subunit within a disaccharidediyl, oligosaccharidediyl, or polysaccharidediyl group can be linked to another monosaccharide subunit within the group via a glycosidic or non-glycosidic bond. Typically, each monosaccharide subunit within a disaccharidediyl, oligosaccharidediyl, or polysaccharidediyl group is linked to another monosaccharide subunit within the group via a glycosidic bond, which can be in the α or β configuration.
[0069] Each oligosaccharidiyl or polysaccharidiyl group may be a linear, branched or macrocyclic oligosaccharidiyl or polysaccharidiyl group. Typically, each oligosaccharidiyl or polysaccharidiyl group is a linear or branched oligosaccharidiyl or polysaccharidiyl group.
[0070] In one embodiment, at least one -R β is a monosaccharidiyl group or a disaccharidiyl group.
[0071] In a further embodiment, at least one -R β is a monosaccharide group. For example, at least one -R β can be a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted. More typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit is unsubstituted.
[0072] In one embodiment, at least one -R β is an aldosyl group, where the aldosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from a glycerosyl, aldotetrosyl (such as erythrosyl or threosyl), aldopentosyl (such as ribosyl, arabinosyl, xylosyl or lyxosyl) or aldohexosyl (such as allosyl, altrosyl, glucosyl, mannosyl, gulosyl, idosyl, galactosyl or talosyl) group, any of which may be optionally substituted and / or modified.
[0073] In another embodiment, at least one -R β is a ketosyl group, where the ketosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from an erythrulosyl, ketopentosyl (such as ribulosyl or xylulosyl) or ketohexosyl (such as psicosyl, fructosyl, sorbosyl or tagatosyl) group, any of which may be optionally substituted and / or modified.
[0074] Each monosaccharide subunit can exist in a closed (cyclic) or open (acyclic) form. Typically, at least one -R βEach monosaccharide subunit in β can be a glycosyl group containing a single closed-ring monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, in such a scenario, at least one -R β is a pyranosyl or furanosyl group, such as an aldopyranosyl, aldofuranosyl, ketopyranosyl, or ketofuranosyl group, any of which may be optionally substituted and / or modified. More typically, at least one -R β is a pyranosyl group, such as an aldopyranosyl or ketopyranosyl group, either of which can be optionally substituted and / or modified.
[0075] In one embodiment, at least one -R β is selected from a ribopyranosyl, arabinopyranosyl, xylopyranosyl, lyxopyranosyl, allopyranosyl, altropyranosyl, glucopyranosyl, mannopyranosyl, gulopyranosyl, idopyranosyl, galactopyranosyl or talopyranosyl group, any of which may be optionally substituted and / or modified.
[0076] In a further embodiment, at least one -R β is a glucosyl group, such as a glucopyranosyl group, where the glucosyl or glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a glucosyl group, where the glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted glucosyl group.
[0077] Each monosaccharide subunit can be in the D-configuration or the L-configuration. Typically, each monosaccharide subunit is present in the configuration most commonly found in nature.
[0078] In one embodiment, at least one -R βis a D-glucosyl group, such as a D-glucopyranosyl group, where the D-glucosyl or D-glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a D-glucosyl group, where the D-glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted D-glucosyl group.
[0079] For the purposes of the present invention, in the substituted monosaccharide diyl group or monosaccharide subunit: (a) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit may each independently be -H, -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -R a -OR b , -R a -SR b , -SO-R b , -SO2-R b , -SO2-OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -NR b -SO-R b , -NR b -SO2-R b , -NR b -SO2-OR b , -R a -SO-R b , -R a -SO2-R b , -R a -SO2-OR b , -SO-N(R b )2, -SO2-N(R b )2, -O-SO-N(R b )2, -O-SO2-N(R b )2, -NR b -SO-N(R b)2, -NR b -SO2-N(R b )2, -R a -SO-N(R b )2, -R a -SO2-N(R b )2, -N(R b )2, -N(R b )3 + , -R a -N(R b )2, -R a -N(R b )3 + , -P(R b )2, -PO(R b )2, -OP(R b )2, -OPO(R b )2, -R a -P(R b )2, -R a -PO(R b )2, -OSi(R b )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (b) one, two, or three hydrogen atoms directly attached to a carbon atom of a monosaccharide diyl group or monosaccharide subunit are each independently -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -OH, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b、-O-R b 、-S-R b 、-R a -O-R b 、-R a -S-R b 、-SO-R b 、-SO2-R b 、-SO2-OR b 、-O-SO-R b 、-O-SO2-R b 、-O-SO2-OR b 、-NR b -SO-R b 、-NR b -SO2-R b 、-NR b -SO2-OR b 、-R a -SO-R b 、-R a -SO2-R b 、-R a -SO2-OR b 、-SO-N(R b )2、-SO2-N(R b )2、-O-SO-N(R b )2、-O-SO2-N(R b )2、-NR b -SO-N(R b )2、-NR b -SO2-N(R b )2、-R a -SO-N(R b )2、-R a -SO2-N(R b )2、-N(R b )2、-N(R b )3 + 、-R a -N(R b )2、-R a -N(R b )3 + 、-P(R b )2、-PO(R b )2、-OP(R b )2、-OPO(R b )2、-R a -P(R b )2、-R a -PO(R b )2、-OSi(Rb )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (c) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit, together with the hydrogen bonded to the same carbon atom as the hydroxyl group, are each independently represented by ═O, ═S, or ═NR b , or =N(R b )2 + and / or (d) any two hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit together form -OR c -, -SR c -, -SO-R c -, -SO2-R c -, or -NR b -R c - is replaced by; where: Each-R a - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 10 carbon atoms; Each-R b- is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 15 carbon atoms; Each-R c - is independently a chemical bond, or a substituted or unsubstituted alkylene, alkenylene, or alkynylene group, optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton, and preferably containing 1 to 10 carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least one, preferably at least two or at least three, -OH, -OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -O-SO-N(R b )2, -O-SO2-N(R b )2, -OP(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.
[0080] Typically, in substituted monosaccharide diyl groups or monosaccharide subunits, (a) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit are each independently -H, -F, -CF, -SH, -NH, -N, -CN, -NO, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(Rb )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (b) one or two hydrogen atoms directly bonded to a carbon atom of a monosaccharide diyl group or a monosaccharide subunit are each independently -F, -CF3, -OH, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (c) the hydroxyl group of one of the monosaccharide subunits or monosaccharide groups is replaced with =0, along with the hydrogen bonded to the same carbon atom as the hydroxyl group; and / or (d) any two hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit together form -OR c -, -NR b -R c - is replaced by; where: Each-R b- is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N; Each-R c - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N, and containing one to eight carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least two, preferably at least three, -OH, -OR b , -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.
[0081] In one embodiment, -R β is a saccharidiyl group, and one or more hydroxyl groups of the saccharidiyl group are each independently -O-CO-R b are substituted with -R b is independently C1-C4 alkyl, preferably methyl. In one embodiment, -R β is a saccharidiyl group, and all hydroxyl groups of the saccharidiyl group are each independently -O-CO-R b are substituted with -R b are independently C1-C4 alkyl, preferably methyl.
[0082] In the modified monosaccharide group or monosaccharide subunit, (a) the ring of the modified monosaccharide subunit or monosaccharide group, or the ring that forms the closed form of the modified monosaccharide subunit, is partially unsaturated; and / or (b) The ring oxygen of the modified monosaccharide diyl group or monosaccharide subunit, or the ring oxygen of the closed ring form of the modified monosaccharide diyl group or monosaccharide subunit, is -S- or -NR d -, where each -R d - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 15 carbon atoms.
[0083] Alternatively, if the modified monosaccharide subunit forms part of a disaccharidediyl, oligosaccharidediyl, or polysaccharidediyl group, -R d may be a further monosaccharide subunit or subunits that form part of a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group, and such further monosaccharide subunit or subunits may optionally be substituted and / or modified.
[0084] Typically, in modified monosaccharide diyl groups or monosaccharide subunits, (a) the ring of the modified monosaccharide diyl group or monosaccharide subunit, or what would become the ring in the closed form of the modified monosaccharide diyl group or monosaccharide subunit, contains a single C=C; and / or (b) The ring oxygen of a modified monosaccharide diyl group or monosaccharide subunit, or the ring oxygen of the closed ring form of a modified monosaccharide diyl group or monosaccharide subunit, is -NR d -, where each -R d- is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing from 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N.
[0085] Typical examples of substituted and / or modified monosaccharide subunits include those corresponding to the following: (i) deoxysugars such as deoxyribose, fucose, fuculose, and rhamnose, in which the monosaccharide diyl group or the hydroxyl group of the monosaccharide subunit is replaced by -H; (ii) amino sugars, such as glucosamine and galactosamine, in which the monosaccharide diyl group or the hydroxyl group of the monosaccharide subunit is substituted with -NH, most typically at the 2-position; and (iii) Sugar acids containing a -COOH group, such as aldonic acids (e.g., gluconic acid), urosonic acid, uronic acids (e.g., glucuronic acid), and aldaric acids (e.g., gulanic or galactaric acid).
[0086] In one embodiment of the first or second aspect of the invention, at least one -R β teeth, [ka] is a saccharidiyl group selected from:
[0087] Preferably, in the compound or complex according to the first or second aspect of the invention, at least one -R β teeth, [ka] is.
[0088] In one embodiment of the first and second aspects of the present invention, at least one -R 3independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β (preferably -R α -OR β or -R α -SR β ) and -R β teeth, [ka] [ka] is selected from.
[0089] In one embodiment of the first and second aspects of the present invention, at least one -R 3 independently, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 6 ]Y. In one embodiment, at least one -R 3 is, independently, [ka] is selected from.
[0090] In one embodiment of the first or second aspect of the invention, each -R 5 is independently unsubstituted or substituted with one or two substituents. In one embodiment, each -R 5 is non-substituted.
[0091] In one embodiment of the first or second aspect of the invention, each -R 6is independently unsubstituted or substituted with one or two substituents. In one embodiment, -R 6 is non-substituted.
[0092] In one embodiment, -R 6 is not substituted with a halo group at the 4-position of the pyridine ring. 6 is not substituted at the 4-position of the pyridine ring. 6 is non-substituted.
[0093] Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex comprises: [ka] wherein Y is a counterion and q is 0, 1, 2, 3, or 4 (preferably q is 1); or a complex or a pharmaceutically acceptable salt thereof.
[0094] Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex comprises: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a complex or a pharmaceutically acceptable salt thereof.
[0095] In one embodiment, the compound or complex according to the first or second aspect of the present invention is in the form of a pharmaceutically acceptable salt. In one embodiment, the compound or complex is in the form of an inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium, or ammonium salt. In one embodiment, the compound or complex is in the form of a sodium salt or potassium salt. In one embodiment, the compound or complex is in the form of a sodium salt. In another embodiment, the compound or complex is in the form of an organic salt, such as an amine salt (e.g., a choline or meglumine salt) or an amino acid salt (e.g., an arginine salt).
[0096] In one embodiment, the compound or complex according to the first or second aspect is phyllochlorin in the form of a pharmaceutically acceptable salt. In one embodiment, the compound or complex is phyllochlorin in the form of a pharmaceutically acceptable inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium, or ammonium salt. In one embodiment, the compound or complex is phyllochlorin monosodium or phyllochlorin monopotassium. In one embodiment, the compound or complex is phyllochlorin monosodium. In another embodiment, the compound or complex is phyllochlorin in the form of a pharmaceutically acceptable organic salt, such as an amine salt (e.g., a choline or meglumine salt) or an amino acid salt (e.g., an arginine salt).
[0097] The compound or complex according to the first or second aspect of the invention has at least two chiral centres. The compound or complex of the first or second aspect of the invention is preferably substantially enantiomerically pure, meaning that the compound contains less than 10%, preferably less than 5%, preferably less than 3%, preferably less than 2%, preferably less than 1% by weight, preferably less than 0.5% by weight of other stereoisomers as measured by XRPD or SFC.
[0098] Preferably, the compound or complex according to the first or second aspect of the invention has an HPLC purity of greater than 97%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, more preferably greater than 99.8%, and most preferably greater than 99.9%. As used herein, % HPLC purity is measured by the area normalization method.
[0099] A third aspect of the invention provides a composition comprising a compound or complex according to the first or second aspect of the invention and a pharmaceutically acceptable carrier or diluent.
[0100] In one embodiment, the composition according to the third aspect of the present invention further comprises polyvinylpyrrolidone (PVP). In one embodiment, the composition comprises 0.01 to 10 wt% PVP as a percentage of the total weight of the composition, preferably 0.1 to 5 wt% PVP as a percentage of the total weight of the composition, preferably 0.5 to 5 wt% PVP as a percentage of the total weight of the composition. In one embodiment, the PVP is K30.
[0101] In one embodiment, the composition according to the third aspect of the present invention further comprises dimethyl sulfoxide (DMSO), hi one embodiment, the composition comprises 0.01 to 99 w / w% DMSO as a percentage of the total weight of the composition, preferably 40 to 99 w / w% DMSO as a percentage of the total weight of the composition, preferably 65 to 99 w / w% DMSO as a percentage of the total weight of the composition.
[0102] In one embodiment, the composition according to the third aspect of the invention further comprises an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.
[0103] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic therapy or cytoluminescent therapy.
[0104] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication. It is suitable for the treatment of: rheumatoid arthritis; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0105] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of diseases characterised by areas of benign or malignant cell hyperproliferation or angiogenesis.
[0106] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the treatment of benign or malignant tumours.
[0107] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0108] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic diagnosis.
[0109] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication. the test is suitable for detecting: rheumatoid arthritis; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0110] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for detecting areas affected by benign or malignant cell hyperproliferation or angiogenesis.
[0111] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the detection of benign or malignant tumours.
[0112] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0113] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the fluorescent or phosphorescent detection of the diseases listed above, preferably for the fluorescent or phosphorescent detection and quantification of said diseases.
[0114] Preferably, the compound or complex according to the first or second aspect of the invention, and the pharmaceutical composition according to the third aspect of the invention, are adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.
[0115] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic therapy or cytoluminescence therapy, then they are preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.
[0116] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic diagnosis, then they are preferably suitable for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.
[0117] Preferably, the radiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both of which are suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0118] The pharmaceutical composition according to the third aspect of the present invention may be in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, respiratory (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration. The pharmaceutical composition may also be in a form suitable for administration by enema or by injection into a tumor. Preferably, the pharmaceutical composition is in a form suitable for oral, parenteral (such as intravenous, intraperitoneal and intratumoral) or respiratory tract administration, preferably in a form suitable for oral or parenteral administration, preferably in a form suitable for oral administration.
[0119] In one preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration. Preferably, the pharmaceutical composition is provided in the form of tablets, capsules, hard or soft gelatin capsules, caplets, lozenges, or drops; as a powder or granules; or as an aqueous solution, suspension, or dispersion. More preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for oral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.
[0120] In another preferred embodiment, the pharmaceutical composition is in a form suitable for parenteral administration. Preferably, the pharmaceutical composition is in a form suitable for intravenous administration. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution for parenteral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is an aqueous solution or suspension having a pH of 6 to 8.5. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.
[0121] In another preferred embodiment, the pharmaceutical composition is in a form suitable for administration to the respiratory tract. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for administration to the respiratory tract, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.
[0122] A fourth aspect of the present invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or areas of angiogenesis. and / or a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0123] A fourth aspect of the present invention provides the use of a compound or complex according to the first or second aspect of the present invention in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy. Preferably, the phototherapeutic agent is selected from the group consisting of atherosclerosis, multiple sclerosis, diabetes, diabetic retinopathy, arthritis, rheumatoid arthritis, fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections, HIV, AIDS, SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles, hepatitis, viral hepatitis, cardiovascular disease, coronary artery stenosis, carotid artery stenosis, intermittent claudication, dermatological conditions, acne, psoriasis, benign or is suitable for the treatment of diseases characterized by areas of malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0124] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of diseases characterised by areas of benign or malignant cell hyperproliferation or neovascularisation.
[0125] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of benign or malignant tumours.
[0126] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0127] A fourth aspect of the invention also provides the use of a compound or complex according to the first or second aspect of the invention in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.
[0128] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for use in treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; Suitable for detecting diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0129] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting areas affected by hyperproliferation of benign or malignant cells or by areas of neovascularization.
[0130] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting benign or malignant tumors.
[0131] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0132] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for fluorescent or phosphorescent detection of said disease, preferably for fluorescent or phosphorescent detection and quantification of said disease.
[0133] Preferably, the drug, phototherapeutic agent or photodiagnostic agent is adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.
[0134] If the drug or phototherapeutic agent is for use in photodynamic therapy or cytoluminescence therapy, then it is preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.
[0135] If the photodiagnostic agent is used for photodynamic diagnosis, then it is preferably adapted for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.
[0136] Preferably, the irradiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both adapted to irradiate wavelengths in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, irradiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, irradiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0137] A fifth aspect of the present invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant
[0013] Methods for treating diseases characterized by areas of sexual cell hyperproliferation or angiogenesis; benign or malignant tumors; early-stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas are provided. The methods comprise administering a therapeutically effective amount of a compound or complex according to the first or second aspect of the invention to a human or animal in need thereof.
[0138] The fifth aspect of the present invention also provides a method for photodynamic or cytoluminescent therapy of a human or animal disease, the method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to the first or second aspect of the present invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis. a disease characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; a benign or malignant tumor; early-stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0139] Preferably, the method of the fifth aspect of the invention is a method of treating areas of benign or malignant cellular hyperproliferation or neovascularization.
[0140] Preferably, the method of the fifth aspect of the invention is a method of treating a benign or malignant tumor.
[0141] Preferably, the method of the fifth aspect of the invention is a method of treating early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0142] The fifth aspect of the present invention also provides a method for photodynamic diagnosis of a human or animal disease, the method comprising administering to the human or animal a diagnostically effective amount of a compound or complex according to the first or second aspect of the present invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis. The human or animal disease is preferably a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas. Preferably, the human or animal disease is characterized by benign or malignant cell hyperproliferation or by areas of angiogenesis. Preferably, the human or animal disease is a benign or malignant tumor. Preferably, the human or animal disease is early stage cancer, cervical dysplasia, soft tissue sarcoma, germ cell tumor, retinoblastoma, age-related macular degeneration, lymphoma, Hodgkin's lymphoma, head and neck cancer, oral cancer, or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. Preferably, the method of photodynamic diagnosis is suitable for fluorescent or phosphorescent detection of said disease, preferably fluorescent or phosphorescent detection and quantification of said disease.
[0143] In any of the methods of the fifth aspect of the invention, the human or animal is preferably further subjected to irradiation or sound simultaneously with or after administration of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal is subjected to irradiation after administration of a compound or complex according to the first or second aspect of the invention.
[0144] If the method is a photodynamic therapy or cytoluminescence therapy method, then the human or animal is preferably irradiated 5 to 100 hours after administration of the compound or complex according to the first or second aspect of the invention, preferably 6 to 72 hours, preferably 24 to 48 hours after administration.
[0145] If the method is a method of photodynamic diagnosis, then the human or animal is preferably irradiated 3 to 60 hours, preferably 8 to 40 hours, after administration of the compound or complex according to the first or second aspect of the invention.
[0146] Preferably, the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing irradiation at wavelengths in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, irradiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, irradiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0147] In any of the methods of the fifth aspect of the invention, preferably the human or animal is a human.
[0148] In a sixth aspect of the present invention, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising: (a) a compound or complex according to the first or second aspect of the present invention, and (b) Providing a pharmaceutical combination containing an immune checkpoint inhibitor.
[0149] In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.
[0150] Preferably, the combination of the sixth aspect is for use in the treatment of a disease, disorder or condition that responds to PD-1, PD-L1 or CTLA4 inhibition. Preferably, the combination of the sixth aspect is for use in the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0151] The sixth aspect also provides the use of a combination of the sixth aspect of the invention in the manufacture of a medicament for the treatment of a disease, disorder or condition responsive to PD-1, PD-L1 or CTLA4 inhibition. The sixth aspect also provides the use of a combination of the sixth aspect of the invention in the manufacture of a medicament for the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0152] The sixth aspect also provides a method of treating a disease, disorder, or condition responsive to PD-1, PD-L1, or CTLA4 inhibition, the method comprising administering a therapeutically effective amount of the combination of the sixth aspect of the invention to a human or animal in need thereof. The sixth aspect also provides a method of treating cancer, the method comprising administering a therapeutically effective amount of the combination of the sixth aspect of the invention to a human or animal in need thereof. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0153] For the combination of the sixth aspect of the invention, the compound or complex according to the first or second aspect of the invention and the immune checkpoint inhibitor may be provided together in one pharmaceutical composition, or separately in two pharmaceutical compositions, which may be administered at the same time or at different times.
[0154] Preferably, the combination of the sixth aspect is adapted for administration simultaneously with or prior to the administration of radiation or sound, preferably prior to the administration of radiation, hi one embodiment, the combination of the sixth aspect is adapted for administration 5 to 100 hours prior to radiation, preferably 6 to 72 hours prior to radiation, preferably 24 to 48 hours prior to radiation.
[0155] Preferably, the radiation used in photodynamic therapy or cytoluminescence therapy is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0156] For the avoidance of doubt, it is to be understood that, so far as is practicable, any embodiment of a given aspect of the invention may occur in combination with any other embodiment of the same aspect of the invention. Further, so far as is practicable, any preferred or optional embodiment of any aspect of the invention is to be taken as a preferred or optional embodiment of any other aspect of the invention. [Brief explanation of the drawings]
[0157] [Figure 1] The absorbance spectrum of the phyllochlorin solution is shown. The percentage indicates the amount of DMSO. The remaining solvent is PBS (phosphate buffered saline). [Figure 2]Figure 2 shows the absorbance spectrum of a phyllochlorin solution in the presence of PVP (1% w / v as a percentage of the total volume of the solution). The % indicates the amount of DMSO. The remaining solvent is PBS (phosphate buffered saline). Figure 2 also shows a graph of the % DMSO against the % maximum absorbance for a solution containing phyllochlorin and a solution containing phyllochlorin and 1% w / v PVP (as a percentage of the total volume of the solution). [Figure 3] The cytotoxicity of chlorin e4 disodium without PVP, chlorin e4 disodium with 1 w / v% PVP (as a percentage of the total volume of the solution), phyllochlorin without PVP, and phyllochlorin with 1 w / v% PVP (as a percentage of the total volume of the solution) is shown. [Figure 4] The phototoxicity of chlorin e4 disodium without PVP, chlorin e4 disodium with 1 w / v% PVP (as a percentage of the total volume of the solution), phyllochlorin without PVP, and phyllochlorin with 1 w / v% PVP (as a percentage of the total volume of the solution) is shown. [Figure 5] (A) In vitro uptake and retention time of Compound 1 and Compound 1c. SKOV3 ovarian cancer cells were incubated with Compound 1 or Compound 1c for up to 24 hours. The intrinsic fluorescence of phyllochlorin was used to monitor cellular uptake and loss over time. Each point was measured in triplicate. In each case, the mean ± SD is shown. (B) No apparent difference in cellular localization was observed between Compound 1 and Compound 1c. [Figure 6] (A) In vitro uptake and retention time of Compound 1 and Compound 2. SKOV3 ovarian cancer cells were incubated with Compound 1 or Compound 2 for up to 24 hours. The intrinsic fluorescence of phyllochlorin was used to monitor cellular uptake and loss over time. Each point was measured in triplicate. In all cases, the mean ± SD is shown. (B) Compound 2 showed a distinct punctate distribution within the cells, whereas Compound 1 was diffusely distributed throughout the cytoplasm. [Figure 7](A) Functionalization with saccharidiyl groups enhances the cellular uptake of phyllochlorin analogs in vitro. SKOV3 ovarian cancer cells were incubated with compounds 2, 6, 8, or 17, and cellular uptake was monitored over a 4-hour period. Each time point was measured in triplicate. In all cases, the mean ± SD is shown. (B) Compound 2 showed a distinct punctate distribution within the cells, whereas compounds 6, 8, and 17 were diffusely distributed throughout the cytoplasm. [Figure 8] Figure 1 shows the localization and retention of compound 6 in tumors. Figure 2 details the quantitative analysis of tumor-associated fluorescence of compound 6 after oral, IV, and IT or IP administration. Tumors were either primary breast (upper panel) or disseminated peritoneal metastases (lower panel). n = 3 / group. Mean ± SD. Figure 3 shows the red fluorescence of compound 6 stimulated by blue light at necropsy. In primary tumors, compound 6 was visualized as intense red fluorescence when illuminated with blue light. In metastatic disease, compound 6 localized to multiple individual metastatic nodules on the peritoneal surface and to contiguous omental masses consistent with metastatic ovarian cancer. Figure 4 shows the localization and retention of compound 6 compared to talaporfin sodium and 5-ALA after IT injection in primary breast tumors. [Figure 9] This shows that photodynamic therapy using Compound 6 completely regressed established tumors. Mice bearing established breast tumors were treated with Compound 6 and laser (treated) or Compound 6 alone (control) (day 6 after implantation). Tumor size was monitored until endpoint (tumor size >100 mm2). Treatment resulted in regression of established tumors to undetectable levels within 14 days after treatment. n=2 / group. Mean ± SD. [Figure 10] 1H NMR of compound 15 is shown. DETAILED DESCRIPTION OF THE INVENTION
[0158] Details of the synthesis experiment Synthesis Example 1 - Synthesis of phyllochlorin sodium salt (compound 1) [ka] Phyllochlorin (121 mg, 88.7% purity, 0.211 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) while swirling. Using a graduated pipette, sodium hydroxide solution (2.1 mL, 0.101 M, 1 equiv.) was added dropwise with manual stirring. The material was sonicated (10 min) to a clear, dark brown color. The solution was lyophilized overnight to yield phyllochlorin sodium salt (compound 1) as a fine black powder (97 mg, 90%).
[0159] 1 H NMR(400MHz,d6-DMSO)δ-2.42(s,1H),-2.26(s,1H),1.62(m,1H),1.69(m,6H),2.12(m,1H),2.43(m,2H),3.32(s,3H),3.48(s,3H),3.60(s, 3H),3.81(q,2H),3.98(s,3H),4.59(m,2H),6.14(dd,1H),6.40(dd,1H),8.31(dd,1H),9.02(s,1H),9.09(s,1H),9.71(s,1H),9.73(s,1H).
[0160] Synthesis Example 1a - Synthesis of phyllochlorin potassium salt (compound 1a) [ka] Phyllochlorin (127 mg, 91.5% purity, 0.230 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) with stirring. Using a graduated pipette, potassium hydroxide solution (2.3 mL, 0.100 M, 1 equiv.) was added dropwise with stirring. The material was sonicated (15 min) to a clear, dark brown color. The solution was lyophilized overnight to yield phyllochlorin potassium salt (compound 1a) as a fine black powder (127 mg, 93%).
[0161] 1H NMR(400MHz,d6-DMSO)δ9.72(s,1H),9.71(s,1H),9.08(s,1H),9.00(s,1H),8.30(dd,1H),6.40(dd,1H),6.13(dd,1H),4.57(m,2H),3.96(s ,3H),3.80(q,2H),3.60(s,3H),3.48(s,3H),3.31(s,3H),2.40(m,2H ),2.10(m,1H),1.69(m,6H),1.60(m,1H),-2.27(s,1H),-2.43(s,1H).
[0162] Synthesis Example 1b - Synthesis of phyllochlorin lithium salt (compound 1b) [ka] Phyllochlorin (127 mg, 91.5% purity, 0.230 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) with stirring. Using a graduated pipette, lithium hydroxide solution (2.3 mL, 0.100 M, 1 equiv.) was added dropwise with stirring. The material was sonicated (15 min) to obtain a clear, dark brown color. The solution was lyophilized overnight to yield phyllochlorin lithium salt (compound 1b) as a fine black powder (115 mg, 90%).
[0163] 1 H NMR(400MHz,d6-DMSO)δ9.73(s,1H),9.71(s,1H),9.10(s,1H),9.02(s,1H),8.32(dd,1H),6.43(dd,1H),6.16(dd,1H),4.59(m,2H),3.98(s ,3H),3.81(q,2H),3.60(s,3H),3.51(s,3H),3.32(s,3H),2.35(m,2H ),2.00(m,1H),1.69(m,6H),1.62(m,1H),-2.26(s,1H),-2.43(s,1H).
[0164] Synthesis Example 1c - Synthesis of phyllochlorin choline salt (compound 1c) [ka] Phyllochlorin (127 mg, 91.5% purity, 0.230 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) with stirring. Choline hydroxide (20 w / w% in HO, 139 mg, 0.230 mmol, 1 equiv.) was added dropwise with stirring. The material was sonicated (5 min) to obtain a clear, dark brown color. The solution was lyophilized overnight to obtain phyllochlorin choline salt (compound 1c) as a black powder (152 mg, quantitative yield).
[0165] 1 H NMR(400MHz,d6-DMSO)δ9.73(s,1H),9.71(s,1H),9.10(s,1H),9.02(s,1H), 8.31(dd,1H),6.41(dd,1H),6.13(dd,1H),4.58(m,2H),3.98(s,3H),3.81(m ,4H),3.60(s,3H),3.51(s,3H),3.38(m,2H),3.31(s,3H),3.09(s,12H),2.3 8(m,2H),2.05(m,1H),1.69(m,6H),1.61(m,1H),-2.26(s,1H),-2.42(s,1H).
[0166] Synthesis Example 1d - Synthesis of phyllochlorin arginine salt (compound 1d) [ka] Phyllochlorin (127 mg, 91.5% purity, 0.230 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) with stirring. Arginine (40 mg, 0.230 mmol, 1 equiv.) was added. Further water (10 mL) was added, and the solution was then heated at 60 °C for 1 h. Acetone (2 mL) was added, and stirring was continued at ambient temperature for 30 min. The acetone was removed under reduced pressure, and the remaining solution was lyophilized overnight to yield phyllochlorin arginine salt (compound 1d) as a black powder (140 mg, 82%).
[0167] 1H NMR(400MHz,d6-DMSO)δ9.73(s,1H),9.71(s,1H),9.10(s,1H),9.01(s,1H), 8.31(dd,1H),8.20(brs,3H),6.41(dd,1H),6.13(dd,1H),4.58(m,2H),3.95( s,3H),3.80(m,2H),3.59(m,5H),3.51(s,3H),3.32(s,3H),3.08(m,2H),2.3 9(m,1H),2.20(m,1H),1.70(m,8H),1.58(m,2H),-2.28(s,1H),-2.44(s,1H).
[0168] Synthesis Example 1e - Synthesis of phyllochlorin meglumine salt (compound 1e) [ka] Phyllochlorin (127 mg, 91.5% purity, 0.230 mmol) was weighed into a 100 mL pear-shaped RBF, followed by distilled, deionized water (15 mL) with stirring. Meglumine (45 mg, 0.230 mmol, 1 equiv.) was added. Further water (10 mL) was added, and the solution was then heated at 60 °C for 1 h. Acetone (2 mL) was added, and stirring was continued at ambient temperature for 30 min. The acetone was removed under reduced pressure, and the remaining solution was lyophilized overnight to yield phyllochlorin meglumine salt (compound 1e) as a black powder (140 mg, 80%).
[0169] 1H NMR(400MHz,d6-DMSO)δ9.73(s,1H),9.71(s,1H),9.10(s,1H),9.02(s,1H),8.32(dd,1 H),6.42(dd,1H),6.16(dd,1H),4.60(m,3H),3.95(s,3H),3.81(m,4H),3.65(m,2H),3.6 0(m,6H),3.51(s,3H),3.49(m,3H),3.42-3.36(m,5H),3.31(s,3H),2.73(m,2H),2.60( m,1H),2.40(m,1H),2.37(s,3H),2.25(m,2H),1.69(m,8H),-2.28(s,1H),-2.44(s,1H).
[0170] Synthesis Example 2 - Synthesis of phyllochlorin methyl ester (compound 2) [ka] To a single-neck 100 mL RBF was added phyllochlorin (2.40 g, 4.72 mmol, 1 equiv.), potassium carbonate (0.78 g, 5.66 mmol, 1.2 equiv.), DMF (30 mL), and a small stir bar. The flask was placed under N2 and stirred at 300 rpm. Methyl iodide (382 μL, 6.13 mmol, 1.3 equiv.) was then added, and the flask was stirred at room temperature. HPLC analysis after 2 h and over the weekend confirmed the reaction was complete. The solution was diluted with DCM (30 mL), filtered through Celite® (1 cm depth), and washed with DCM until no color eluted. The solvent was removed under reduced pressure, yielding approximately 4 g of a blue solid. The crude material was dissolved in EtOAc (125 mL), washed with water (2 x 100 mL), dried (Na2SO4), and concentrated under reduced pressure to give the crude product as a dark blue / green solid (2.7 g). The crude material was purified by column chromatography (silica, 4 x 23 cm, stepwise elution from DCM to 3% MeOH / DCM) to give phyllochlorin methyl ester (compound 2) as a dark blue / green solid (1.60 g, 64.8%).
[0171] 1H NMR(400MHz,CDCl3)δ-2.22(br,1H),-2.10(br,1H),1.72-1.80(m,6H),2.20 -2.10(m,1H),2.10-2.00(m,1H),2.48-2.62(m,2H),3.38(s,3H),3.53(s,3H) ,3.58(s,3H),3.64(s,3H),3.84(q,2H),3.98(s,3H),4.50(q,1H),4.56(d,1 H),6.13(dd,1H),6.37(dd,1H),8.16(dd,1H),8.83(brs,2H),9.71(brs,2H).
[0172] Synthesis Example 3 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propyl)propanamide (Compound 3) [ka] Synthesis of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-aminopropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate [ka] Step 1: A two-neck 500 mL RBF equipped with a nitrogen inlet and rubber septum was charged with a solution of 1,2,3,4,6-penta-O-acetyl-β-D-glucose (6.23 g, 15.95 mol, 1 equiv.) in dry DCM (150 mL) and a stir bar, and the mixture was placed under N2. To this solution was added (9H-fluoren-9-yl)methyl (3-mercaptopropyl)carbamate (ChemBioChem, 2010, 11(6), 778-781) (6.00 g, 19.1 mmol, 1.2 equiv.), followed by the dropwise addition of BF3·OEt2 (5.9 mL, 47.9 mmol, 3 equiv.) through the rubber septum over 2–3 min. The mixture was stirred (315 rpm) at room temperature under N2 overnight. TLC analysis at this point indicated only traces of starting material remained. The reaction was quenched by the addition of 1 M HCl (50 mL) and transferred to a separatory funnel. The organic phase was collected and washed with brine (50 mL), then dried (MgSO4) and concentrated by rotary evaporation to give the crude glycosylated product as a pale syrup (18 g). The residue was purified by column chromatography (50% EtOAc / hexane, loaded as a solution in eluent, R f =0.5) to give N-Fmoc-3'-amino-1-thio-2,3,4,6-tetra-O-acetyl-β-D-glucopyranose as a colorless syrup (5.55 g, 54%) that solidified on standing.
[0173] 1H NMR(400MHz,CDCl3)δ7.76(d,J=7.4Hz,2H),7.60(d,J=7.4Hz,2H),7.39(dd,J=7.4,7.4Hz,2H),7.31(dd,J=7 .4,7.4Hz,2H),5.22(dd,J=9.4,9.4Hz,1H),5.05(dd,J=9.4,9.4Hz,1H),5.02(dd,J=9.4,9.4Hz,1H),4.93(br s,1H),4.50-4.42(m,3H),4.31-4.08(m,3H),3.69(ddd,J=10.1,4.8,2.7Hz,1H),3.36-3.19(m,2H),2.74(ddd,J=13.4,6. 7,6.7Hz,1H),2.64(ddd,J=13.4,6.7,6.7Hz,1H),2.05(s,3H),2.04(s,3H),2.03(s,3H),2.00(s,3H),1.87-1.70(m,2H).
[0174] Step 2: To a 50 mL flask containing N-Fmoc-3'-amino-1-thio-2,3,4,6-tetra-O-acetyl-β-D-glucopyranose (633 mg, 0.983 mmol, 2 equiv.) and a stir bar was added 20% piperidine / DMF (15 mL), and the resulting solution was stirred (420 rpm) under ambient atmosphere for 10 minutes. An aliquot was taken and 1 Concentration for H NMR analysis indicated cleavage of the Fmoc group. The reaction mixture was concentrated and then reconstituted / concentrated five times from toluene (to remove all piperidine) to give (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-aminopropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate as a gummy beige solid, which was used without further purification.
[0175] Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propyl)propanamide (Compound 3) [ka] Step 1: To a 50 mL RBF containing (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-aminopropyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate and equipped with a nitrogen inlet was placed phyllochlorin (250 mg, 0.491 mmol, 1 equiv.), DCM (12 mL), and a stir bar. To the resulting dark solution was added PyBOP (307 mg, 0.590 mmol, 1.2 equiv.), followed by triethylamine (204 μL, 1.47 mmol, 3 equiv.), and the mixture was stirred (420 rpm) under N for 1 h. TLC analysis at 30 min indicated only traces of starting material remained, and the desired product (5% MeOH / DCM, R f (starting material) = 0.37, R f The reaction mixture was transferred to a 100 mL separatory funnel and washed with 1 M HCl (2 × 20 mL) (the organic phase turned deep purple at this point), followed by pH 7 buffer (20 mL) (the organic phase turned green). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give the crude amide as a brown film (approximately 1.10 g). The residue was purified by Biotage autocolumn chromatography to give phyllochlorin β-1-thioglucose propylamide conjugate peracetate as a blue-black solid (417 mg, 95%). The crude material was deprotected without further purification.
[0176] Step 2: To a solution of phyllochlorin β-1-thioglucose propylamide conjugate peracetate (417 mg, 0.457 mmol, 1 equiv.) in MeOH (4 mL) / DCM (4 mL), NaOMe (4.6 M in MeOH, 0.50 mL, 2.286 mmol, 5 equiv.) was added and the mixture was stirred (420 rpm) under N for 30 min. TLC analysis showed clean conversion to the deacetylated product (5% MeOH / DCM, R f (starting material) = 0.6, R f(Product) = 0). The reaction was quenched with AcOH (5 drops) and concentrated by rotary evaporation. The residue was purified by column chromatography (3 × 17 cm, packed in 5% MeOH / DCM, using a gradient of 5–10% MeOH / DCM) to give compound 3 as a dark blue solid (255 mg, 70% over two steps).
[0177] 1 H NMR(400MHz,d6-DMSO)δ9.75(s,1H),9.73(s,1H),9.10(s,1H),9.08(s,1H),8.33(dd,1H),7.90(t ,1H),6.45(d,1H),6.18(d,1H),5.10(d,1H),5.01(d,1H),4.92(d,1H),4.60(m,1H),4.50(m,2H),4 .20(d,1H),3.92(s,3H),3.80(m,2H),3.61(s,3H),3.55(s,3H),3.20-3.00(m,6H),2.95(m,1H),2 .70-2.50(m,2H),2.50-2.40(m,2H),2.10(m,1H),1.80-1.60(m,10H),-2.25(s,1H),-2.45(s,1H).
[0178] Synthesis Example 4 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methylpropanamide (Compound 4) [ka] To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (500 mg, 0.983 mmol, 1 equiv.), dichloromethane (15 mL), PyBOP (563 mg, 1.1 equiv.), triethylamine (409 μL, 3 equiv.), and 2-(2-(2-(methylamino)ethoxy)ethoxy)ethanol (193 mg, 1.2 equiv.). The mixture was stirred at room temperature for 1 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 10 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (1.10 g). The crude mixture was loaded directly onto a silica column and eluted with 3–7% MeOH / DCM. TLC (R in 5% MeOH / DCM) f The pure fractions containing the green / blue compound from HCl (0.20) were combined to give the final product, Compound 4.
[0179] 1 H NMR(400MHz,CDCl3)δ9.71(m,2H),8.83(m,2H),8.16(dd,1H),6.38(dd,1H),6. 13(dd,1H),4.66(m,1H),4.54(m,1H),4.01(s,3H),3.84(q,2H),3.63(s,3H),3 .55-3.50(m,4H),3.47-3.30(m,10H),3.04(m,1H),2.77-2.50(m,6H),2.40-2. 20(m,4H),1.93-1.35(m,1H),1.30-1.22(m,6H),-2.10(br,1H),-2.24(br,1H).
[0180] Synthesis Example 5 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(3-hydroxypropyl)-N-methylpropanamide (Compound 5) [ka] To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), PyBOP (2.26 mg, 1.1 equiv.), triethylamine (1.64 mL, 3 equiv.), and 3-(methylamino)-propanol (0.42 g, 1.2 equiv.). The mixture was stirred at room temperature for 3 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (5.1 g). The crude mixture was loaded directly onto a silica column and eluted with 1.5–2% MeOH / DCM. f Pure fractions containing a green / blue spot by TLC (5% MeOH / DCM) of 0.30 were combined to give compound 5 (1.29 g, 57%) (HPLC purity: 86.8%).
[0181] 1 H NMR(400MHz,CDCl3)δ9.75-9.70(m,2H),8.85(brs,1H),8.16(dd,1H),6.38(dd,1H),6 .15(dd,1H),4.70-4.65(m,1H),4.58-4.50(m,1H),4.00(s,3H),3.89-3.82(m,3H),3.6 5(s,3H),3.53(s,3H),3.37(s,3H),3.31-3.15(m,4H),2.65-2.53(m,2H),2.37-2.22( m,3H),2.16(3,3H),1.80-1.70(m,7H),1.48-1.40(m,2H),-2.10(s,1H),-2.22(m,1H).
[0182] Synthesis Example 6 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propyl)propanamide (also referred to as phyllochlorin β-D-1-thioglucose-N-methylpropylamide conjugate) (Compound 6) [ka] Step 1: A single-neck 50 mL RBF was charged with compound 5 (1.25 g, 2.156 mmol, 1 equiv.), dichloroethane (10 mL), and DMF (1 drop). Thionyl chloride (0.23 mL, 3.233 mmol, 1.5 equiv.) was added, and the resulting solution was stirred (350 rpm) at 40 °C under N2. After 2 h, the flask was heated at 60 °C for an additional 2 h. The reaction was then cooled using an ice / water bath, and pH = 7 phosphate buffer (10 mL) was added. The mixture was extracted with DCM (3 × 15 mL), dried (Na2SO4), and the solvent was removed under reduced pressure to give approximately 1.4 g of crude product. The remaining blue solid was purified by column chromatography using 2–4% MeOH / DCM, and the fractions containing the first dark band to elute were combined to give phyllochlorin N-3-chloropropyl-N-methylpropylamide as a blue / green solid (0.875 g, 67.8%).
[0183] Step 2: A single-neck 25 mL RBF was charged with phyllochlorin N-3-chloropropyl-N-methylpropylamide (145 mg, 0.242 mmol, 1 equiv.), 2-butanone (5 mL), and sodium iodide (73 mg). The resulting solution was stirred (350 rpm) at 90 °C under N2. After 3 h, TLC indicated the reaction was complete, and the flask was then cooled using an ice / water bath. To the crude iodide was added thioglucose tetraacetate (106 mg, 0.291 mmol, 1.2 equiv.) and DIPEA (38 mg, 0.291 mmol, 1.2 equiv.), and the solution was stirred at 25 °C overnight. TLC analysis indicated the presence of some starting material, and the solution was heated at 50 °C for 3 h. The solvent was removed, and the remaining blue solid was purified by column chromatography using 2-5% MeOH / DCM to isolate the darkest band (R f Fractions containing approximately 0.6% methylcellulose (5% MeOH / DCM) were combined to give phyllochlorin β-1-thioglucose N-methylpropylamide conjugate peracetate as a blue / green solid (145 mg) that was used directly in the next step.
[0184] Step 3: To a solution of phyllochlorin β-1-thioglucose N-methylpropylamide conjugate peracetate (140 mg, 0.1512 mmol, 1 equiv.) in MeOH (2 mL) / DCM (2 mL), NaOMe (4.6 M in MeOH, 0.16 mL, 0.756 mmol, 5 equiv.) was added and the mixture was stirred (250 rpm) under N for 30 min. TLC analysis showed conversion to the deacetylated product (5% MeOH / DCM, R f (starting material) = 0.6, R f (Product) = 0). The reaction was quenched with acetic acid (10 drops) and concentrated by rotary evaporation. The residue was purified by column chromatography (2-8% MeOH / DCM) to elute compound 6 as a dark blue solid (30 mg, 16% - from chloride in two steps).
[0185] 1H NMR(400MHz,d6-DMSO)δ9.76(s,1H),9.74(s,1H),9.10(d,J=5.7Hz,1H),9.07(s,1H),8.35(dd,J=17.8,11.6Hz,1H),6.45(dd,J=17.8,1 .6Hz,1H),6.18(dd,J=11.6,1.5Hz,1H),5.24-4.89(m,3H),4.66(p,J=7.4Hz,1H),4.59-4.44(m,2H),4.28(dd,J=32.2,9.6Hz,1H),3.98( d,J=6.1Hz,3H),3.83(q,J=7.6Hz,2H),3.63(d,J=1.0Hz,3H),3.55(d,J=1.6Hz,3H),3.26-3.01(m,3H),2.90(s,2H),2.81(s,1H),2.72- 2.52(m,1H),2.42(dt,J=20.1,5.8Hz,1H),1.81(ddd,J=22.3,14.6,6.9Hz,1H),1.75-1.61(m,7H),-2.26(s,1H),-2.42(d,J=2.2Hz,1H).
[0186] Synthesis Example 7 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(5-hydroxypentyl)-N-methylpropanamide (also known as phyllochlorin N-5-hydroxypentyl-N-methylpropylamide) (Compound 7) [ka] To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (0.87 g, 1.71 mmol, 1 equiv.), dichloromethane (25 mL), PyBOP (0.98 g, 1.1 equiv.), triethylamine (0.71 mL, 3 equiv.), and 5-(methylamino)pentanol (0.24 g, 1.2 equiv.). The mixture was stirred at room temperature for 90 minutes. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / green film (2.1 g). The crude mixture was loaded directly onto a silica column (3 × 22 cm, pre-equilibrated with 1% MeOH / DCM) and eluted with the same solvent until the first pale band eluted, then the solvent was changed to 1.5% MeOH / DCM. Once the most intense blue / green band began to elute, the solvent was changed to 2% MeOH / DCM. f Pure fractions containing a green / blue spot by TLC (5% MeOH / DCM) of 0.30 were combined to give compound 7 (0.93 g, 89%) (HPLC purity: 98.2%).
[0187] 1 H NMR(400MHz,CDCl3)δ9.72(br s,2H),8.87-8.82(m,1H),8.16(dd,1H),6.39(dd,1H),6.15(dd,1H),4.72-4.65(m,1H),4.59-4.50(m,1 H),4.00(s,3H),3.88-3.80(m,2H),3.64(s,3H),3.53(m,4H),3.37(s,3H),3.19-3.08(m,1H),2.65-2.47 (m,4H),2.40-2.15(m,3H),2.14-2.05(m,2H),1.80-1.70(m,6H),1.52-1.42(m,1H),1.40-1.25(m,2H), 1.23-1.16(m,1H),0.58-0.50(m,1H),0.30-0.22(m,1H),0.15-0.07(m,1H),-2.10(s,1H),-2.25(m,1H).
[0188] Synthesis Example 8 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(5-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)pentyl)propanamide (Compound 8) [ka] Step 1: A single-neck 50 mL RBF was charged with phyllochlorin N-5-hydroxypentyl-N-methylpropylamide (0.90 g, 1.481 mmol, 1 equiv.), dichloroethane (10 mL), and DMF (1 drop). Thionyl chloride (0.16 mL, 2.221 mmol, 1.5 equiv.) was added, and the resulting solution was stirred (300 rpm) under N at 40 °C. After 30 min, TLC showed the product (R f 0.6, 5% MeOH / DCM) indicated this was the major compound present, and the flask was heated at 55 °C for an additional 30 min. The reaction was then cooled using an ice / water bath, and pH = 7 phosphate buffer (10 mL) was added. The mixture was extracted with DCM (3 x 10 mL), dried (NaSO), and the solvent removed under reduced pressure to give the crude product. The remaining blue solid was purified by column chromatography (3 x 20 cm silica) using 1-4% MeOH / DCM. A brown band eluted first, followed by the product (R f Approximately 0.6-0.7% of the total eluate was obtained. Fractions containing the dark band were combined to give phyllochlorin N-5-chloropentyl-N-methylpropylamide as a blue / green oily solid.
[0189] 1H NMR(400MHz,CDCl3)δ9.72(br s,2H),8.82(brs,2H),8.16(dd,1H),6.39(m,1H),6.13(d,1H),4.70-4.65(m,1H),4.59-4.48(m,1H),4. 00(s,3H),3.88-3.80(m,2H),3.64(s,3H),3.53(m,4H),3.42(t,2H),3.36(s,3H),3.17-3.08(m,2H),2.7 8(t,1H),2.65-2.47(m,3H),2.35-2.20(m,4H),2.14-2.05(m,2H),1.80-1.70(m,7H),1.70-1.62(m,2H), 1.28-1.22(m,2H),0.78-0.70(m,1H),0.68-0.58(m,1H),0.35-0.28(m,1H),-2.10(s,1H),-2.25(m,1H).
[0190] Step 2: A single-neck 250 mL RBF was charged with phyllochlorin N-5-chloropentyl-N-methylpropylamide (0.71 g, 1.13 mmol, 1 equiv.), 2-butanone (25 mL), and sodium iodide (340 mg). The resulting solution was stirred (350 rpm) at 90 °C (external temperature, oil bath) under N2. After 3 h, TLC indicated the presence of very little starting material, and the flask was then cooled using an ice / water bath. To the crude iodide was added thioglucose tetraacetate (496 mg, 1.36 mmol, 1.2 equiv.) and DIPEA (176 mg, 1.36 mmol, 1.2 equiv.), and the solution was stirred at 25 °C for 1 h. TLC analysis indicated the presence of some starting material, and the solution was then heated at 40 °C for 1.5 h. The solvent was removed, and the crude product was purified. The remaining blue solid was purified by column chromatography (4 x 21 cm silica) using 2-4% MeOH / DCM to isolate the darkest band (R f Fractions containing approximately 0.5% MeOH / DCM) were combined to give phyllochlorin β-1-thioglucose N-pentyl N-methylpropylamide conjugate peracetate as a blue / green solid (1.20 g).
[0191] Step 3: To a solution of phyllochlorin β-1-thioglucose N-pentyl N-methylpropylamide conjugate peracetate (1.05 g, 1.10 mmol, 1 equiv.) in MeOH (15 mL) / DCM (15 mL), NaOMe (4.6 M in MeOH, 1.20 mL, 5.50 mmol, 5 equiv.) was added and the mixture was stirred (250 rpm) under N for 30 min. TLC analysis showed conversion to the deacetylated product (5% MeOH / DCM, R f (starting material) = 0.6, R f (Product) = 0). The reaction was quenched with AcOH (30 drops) and concentrated by rotary evaporation. The residue was purified by column chromatography (4 x 18 cm, packed with 2% MeOH / DCM). After loading, the column was washed with 5% MeOH / DCM (high R f (to elute), 6% MeOH / DCM (medium R f Successive elution with 8% MeOH / DCM (to elute 8) and 8% MeOH / DCM eluted compound 8 as a dark blue solid (262 mg, 29% - from chloride in 3 steps).
[0192] Synthesis Example 9 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propyl)propanamide sulfoxide (Compound 9) [ka] To a single-neck 25 mL RBF was added phyllochlorin β-D-1-thioglucose-N-methylpropylamide conjugate (100 mg, 0.132 mmol, 1 equiv.), urea-hydrogen peroxide (18.6 mg, 0.198 mmol, 1.5 equiv.), and acetic acid (1.5 mL). The solution was stirred at 55°C (external temperature, oil bath) for 2 hours. The acetic acid was removed under reduced pressure (rotary evaporator, 40°C, full vacuum) to leave a dark green viscous oil. The crude product was purified by silica column chromatography (3 x 20 cm) using 10-16% MeOH / DCM. The product (R in 10% MeOH / DCM) was f The fractions containing 0.3) were combined to give compound 9 as a dark green / blue flaky solid (91 mg, 89%).
[0193] 1 H NMR(400MHz,d6-DMSO)δ9.76-9.72(m,2H),9.11-9.05(m,2H),8.35(dd,1H),6.44(dd,1H),6.18(dd,1H),5.70-5.30(m ,1H),5.24-5.02(m,2H),4.80-4.60(m,2H),4.60-4.52(m,1H),4.31-4.10(m,1H),3.99-3.95(m,3H),3.81(q,2H),3.7 5-3.65(m,1H),3.62(s,3H),3.55(s,3H),3.51-3.39(m,3H),3.33(s,3H),3.17(m,1H),3.16-2.97(m,2H),2.90(m,2H) ,2.84(s,1H),2.82-2.55(m,2H),2.47-2.38(m,1H),1.99-1.75(m,2H),1.73-1.66(m,7H),-2.25(s,1H),-2.43(s,1H).
[0194] Synthesis Example 10 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(2-hydroxyethyl)-N-methylpropanamide (Compound 10) [ka] To a 250 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (3.00 g, 5.90 mmol, 1 equiv.), dichloromethane (70 mL), PyBOP (3.30 g, 1.1 equiv.), triethylamine (2.46 mL, 3 equiv.), and 2-(methylamino)-ethanol (0.53 g, 1.2 equiv.). The mixture was stirred at room temperature for 3 hours. Analysis by TLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO), filtered through Celite®, and concentrated by rotary evaporation to give the crude product as a blue / brown film (6.0 g). The crude product was loaded directly onto a silica column and eluted with 1–3% MeOH / DCM. TLC (R in 5% MeOH / DCM) f The pure fractions containing a green / blue spot due to HPLC (0.40) were combined to give compound 10 (0.62 g, 25%) (HPLC purity: 83.8%).
[0195] 1 H NMR(400MHz,CDCl3)δ9.78-9.70(m,2H),8.85(m,2H),8.20-8.10(m,1H),6.38(d,1 H),6.14(d,1H),4.70-4.65(m,1H),4.58-4.50(m,1H),4.01(m,3H),3.89-3.82(m,2 H),3.65(s,3H),3.53(s,3H),3.37(m,4H),3.31-3.22(m,1H),3.14-3.08(m,2H),2 .65-2.51(m,3H),2.37-2.22(m,3H),2.09(s,2H),1.88-1.70(m,8H),1.62-1.50(br s,2H),-2.05 - -2.32(m,2H).
[0196] Synthesis Example 1 Synthesis of 1-(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-(3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methylpropanamido)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 11) [ka] To a single-neck 100 mL RBF was added phyllochlorin β-D-1-thioglucose-N-methylpropylamide conjugate (2.00 g, 2.64 mmol, 1 equiv.), pyridine (15 mL), acetic anhydride (2.5 mL, 26.4 mmol, 10 equiv.), and DMAP (10 mg). The solution was stirred at 35 °C (external temperature, heat block) for 90 min. Analysis by TLC and HPLC indicated the reaction was complete. Ethyl acetate (40 mL) and water (30 mL) were added, and the mixture was stirred vigorously for 10 min. The layers were separated, and the ethyl acetate layer was washed with 0.5 M HCl (4 × 30 mL), saturated NaHCO₃ (3 × 30 mL), dried (Na₂SO₄), and concentrated to give the crude product as a dark green solid (2.2 g). The crude product was purified by column chromatography (4 × 30 cm silica) using 1–3% MeOH / DCM. Product (R in 5% MeOH / DCM f The fractions containing 11 (0.6) were combined to give compound 11 as a dark green / blue flaky solid (2.25 g, 92%) (HPLC purity: 98.4%).
[0197] 1H NMR(400MHz,CDCl3)δ9.72(m,2H),8.90-8.85(m,2H),8.23-8.11(m,1H),6.45-6.35(m,1H),6.19-6.15(m,1H) ,5.12(t,0.5H),5.01(t,0.5H),4.93(t,0.5H),4.78(brt,0.5H),4.69(brs,0.5H),4.60-4.50(m,1H),4.30(d, 0.5H),4.20-4.05(m,1H),4.01(m,4H),3.92-3.78(m,2H),3.65(s,3H),3.54(m,4H),3.41(m,3H),3.25-3.08(m ,1H),2.75-2.65(m,0.5H),2.60-2.50(m,4H),2.50-2.35(m,1H),2.30-2.15(m,3H),2.00(s),1.97(s),1.94(2 xs),1.88(s),1.83-1.72(m,9H),1.50-1.40(m,1H),1.35-1.20(m,1H),0.90-0.70(m,1H),0.50-0.25(m,1H),-2.10(br,1H),-2.25(br,1H).
[0198] Synthesis Example 1 Synthesis of 2-((2R,3S,4S,5R,6S)-6-((3-(3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methylpropanamido)propyl)thio)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl L-valinate hydrochloride (Compound 12) [ka] Step 1: To a single-neck 25 mL RBF was added phyllochlorin β-D-1-thioglucose-N-methylpropylamide conjugate (283 mg, 0.374 mmol, 1 equiv.), N-Boc-L-valine-N-carboxyanhydride (100 mg, 0.411 mmol, 1.1 equiv.), DMF (6 mL), and DMAP (crystalline). The solution was stirred at 350 rpm for 5 h in the dark under nitrogen. The DMF was removed under reduced pressure (rotary evaporator, 50 °C) to leave a dark green viscous oil, which was purified by column chromatography (4 x 20 cm silica) using 2-6% MeOH / DCM. The Boc-protected product (R in 5% MeOH / DCM) was purified. f Fractions containing 0.1-0.2) were combined to give a dark green / blue oil (113 mg, 32%) (HPLC purity: 94% as a mixture of regioisomers).
[0199] 1 H NMR(400MHz,CDCl3)δ9.74-9.69(m,2H),8.94-8.83(m,2H),8.20-8.08(m,1H),6.46(m,1H) ,6.14(m,1H),5.10-4.95(m,1H),4.75-4.50(m,2H),4.27-4.05(m,2H),4.03-3.97(m,3H),3 .82(brq,2H),3.62(m,4H),3.52(m,4H),3.37-3.32(m,4H),3.30-3.05(m,3H),2.70-2.35( m,6H),2.35-2.12(m,4H),1.90-1.70(m,10H),1.45-1.36(m,10H),1.00-0.73(m,7H),-2.21 - -2.45(m,2H).
[0200] Step 2: To a single-neck 25 mL RBF was added the Boc-protected product from Step 1 (113 mg, 0.118 mmol, 1 equiv.), 4 M HCl in dioxane (0.3 mL, 1.20 mmol, 10 equiv.), dioxane (1 mL), and DCM (5 mL). The mixture was stirred overnight at room temperature in the dark under nitrogen. The solvent was removed under reduced pressure to leave a dark green / purple viscous oil, which was purified by Biotage autocolumn chromatography (reverse-phase, Sfar C18D 30 g column) using 5-50% MeCN / 0.1 M aqueous HCl. The product (R in 20% MeOH / DCM) was f The fractions containing 1,2-dimethyl-2,4-trimethyl-1,2-trimethyl ...
[0201] Synthesis Example 13 - Synthesis of phyllochlorin 2-deoxyglucosamine-propylamide (Compound 13) [ka] To a 10 mL RBF containing a stir bar was added phyllochlorin (200 mg, 0.3952 mmol, 1 equiv.), PyBOP (225 mg, 0.4325 mmol, 1.1 equiv.), DMF (4.0 mL), and triethylamine (120 μL, 0.8650 mmol, 2.2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 5 minutes, and then D-glucosamine hydrochloride (93 mg, 0.4325 mmol, 1.1 equiv.) was added in one portion. The resulting mixture was stirred for 30 minutes, by which time the reaction was complete as monitored by HPLC. The reaction mixture was concentrated by rotary evaporation to give a black residue, which was dissolved in minimal DMSO and purified by Biotage automated column chromatography using a C-18 column. Product-containing fractions were combined to give compound 13 as a dark green / black solid (38.4 mg, 15%).
[0202] 1H NMR(400MHz,d6-DMSO)δ9.76(s,1H),9.74(s,1H),9.13-9.06(m,2H),8.36(dd,J=17.8,11.6Hz,1H),7.74 -7.66(m,1H),6.50-6.42(m,1H),6.31(dd,J=4.5,1.2Hz,1H),6.18(dd,J=11.6,1.5Hz,1H),4.92-4.84(m, 2H), 4.67-4.34 (m, 4H), 3.94 (d, J = 2.3 Hz, 3H), 3.83 (q, J = 7.6 Hz, 2H), 3.68-3.58 (m, 4H), 3.58-3.50 (m, 4H), 3.50-3.39 (m, 2H), 3.15-2.98 (m, 1H), 2.46-2.31 (m, 1H), 1.79-1.64 (m, 7H), -2.27 (s, 1H), -2.43 (s, 1H). The product in solution exists as a mixture of epimers, giving rise to two sets of signals in an approximately 3:1 ratio.
[0203] Synthesis Example 14 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(2-(2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethyl)propanamide (Compound 14) [ka] Step 1: A solution of N-Cbz-2-(2-methylamino-ethoxy)-ethanol (1.35 g, 5.33 mmol, 1 equiv.) and penta-acetylglucose (2.29 g, 1.1 equiv.) in DCM (30 mL) was cooled in an ice / water bath under nitrogen, and BF EtO (3.78 g, 3.29 mL, 5 equiv.) was added dropwise via syringe. The solution was stirred (420 rpm) at 0-5 °C (external) for 1 h and then at room temperature overnight. Reaction progress was monitored by NMR. Upon completion, the solution was washed with saturated NaHCO (2 × 20 mL), and the combined aqueous washes were then extracted with DCM (20 mL). The combined organic layers were dried (MgSO) and evaporated to give the Cbz-protected PEG-glucose as a pale yellow oil (approximately 4 g), which was partially purified by column chromatography (4 x 25 cm silica) eluting with a gradient of 0.5-3.5% MeOH / DCM. The resulting oil (2.85 g) was used directly in the next step.
[0204] Step 2: To a three-necked 250 mL RBF was added Cbz-protected PEG-glucose (2.85 g), methanol (100 mL), and 10% Pd / C (140 mg, 5 w / w%). A hydrogen balloon was attached to the flask, and the flask was evacuated and refilled with nitrogen three times. The flask was then evacuated and refilled with hydrogen. The solution was stirred at 325 rpm overnight. After evacuating the flask and refilling with nitrogen, the solution was filtered (Celite®), washed with methanol (20 mL), and concentrated under reduced pressure. The concentrated residue was taken up in DCM (25 mL), washed with water (2 × 20 mL), dried (MgSO), and evaporated to give the amine PEG-glucose (1.5 g) as a yellow oil, which was used without further purification.
[0205] Step 3: To a 50 mL RBF was added phyllochlorin (1.04 g, 2.05 mmol, 1 equiv.), PyBOP (1.28 g, 2.46 mmol, 1.2 equiv.), DCM (15 mL), and triethylamine (1.92 mL, 13.9 mmol, 6.7 equiv.). The resulting mixture was stirred (250 rpm) under nitrogen at ambient temperature for 30 min, and then amine PEG glucose in DCM (10 mL) was added in one portion. The resulting mixture was stirred overnight in the dark under nitrogen. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 30 mL) followed by pH 7 buffer (1 × 30 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue / black oil, which was purified by column chromatography (4 × 26 cm silica) eluting with a gradient of 1%–2.5% MeOH / DCM. Phyllochlorin β-D-1-glucose-N-methylethoxyethylamide conjugate tetraacetate (R in 5% MeOH / DCM) f Fractions containing R (approximately 0.4%) were combined to give a blue / black oil (approximately 0.7 g) which was further purified using Biotage autocolumn chromatography. f Approximately 0.4 fractions were combined to give phyllochlorin β-D-1-glucose-N-methylethoxyethylamide conjugate tetraacetate (0.38 g) (HPLC purity: 88%), which was deprotected in the next step without further purification.
[0206] Step 4: To a solution of phyllochlorin β-D-l-glucose-N-methylethoxyethylamide conjugate tetraacetate (350 mg, 0.372 mmol, 1 equiv.) in MeOH (5 mL) and DCM (5 mL), NaOMe (4.6 M in MeOH, 0.40 mL, 1.862 mmol, 5 equiv.) was added and the mixture was stirred (420 rpm) under nitrogen for 1 h. TLC analysis showed conversion to the deacetylated product (10% MeOH / DCM, R f (starting material) = 0.85, R f(Product) = 0.25). The reaction was quenched with AcOH (112 mg, 1.862 mmol, 5 equiv.) and concentrated by rotary evaporation to give a black film, which was purified by column chromatography (3 × 21 cm silica) eluting with a gradient of 3–10% MeOH / DCM to give compound 14 (204 mg, 71%) as a blue / black solid (HPLC purity: 91%).
[0207] 1 H NMR(400MHz,d6-DMSO)δ9.75(s,1H),9.73(s,1H),9.10(s,1H),9.06(s,1H),8.33(dd,1H),6.44(d,1H),6.18(d,1H),5.30-4.70(br m,3H),4.65(m,1H),4.60-4.53(m,2H),4.13(m,1H),3.98(d,3H),3.81( m,4H),3.68-3.62(m,2H),3.62(s,3H),3.54(d,3H),3.50-3.30(m,14H) ,3.18-3.05(m,4H),3.00-2.94(m,3H),2.88-2.78(m,2H),2.55-2.45(m ,1H),2.45-2.38(m,1H),1.75-1.65(m,7H),-2.25(s,1H),-2.42(s,1H).
[0208] Synthesis Example 15 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(3-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propyl)propanamide (also referred to as phyllochlorin β-D-glucosyl-N-methylpropylamide conjugate) (Compound 15) [ka] Step 1: A 250 mL three-neck RBF equipped with an internal thermometer, nitrogen inlet, and rubber septum was charged with tert-butyl (3-hydroxypropyl)(methyl)carbamate (2.68 g, 14.17 mmol, 1.05 equiv.), a stir bar, 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl trichloroacetimidate (10.00 g, 13.5 mmol, 1 equiv.), dry DCM (100 mL), and crushed 4A molecular sieves (5.0 g). The resulting suspension was placed under a nitrogen atmosphere and stirred (420 rpm) for 0.5 h before being cooled to −15 °C (internal temperature) using an EtOH / ice / NaCl bath. A solution of TMSOTf (0.2 M in DCM, 3.3 mL, 0.67 mmol) was added dropwise over 1 min and stirring was continued at low temperature for 0.5 h, at which point TLC analysis indicated the reaction was complete (25% EtOAc / hexane, R f (starting material) = 0.4, R f (product) = 0.2, visualized by UV). The reaction was quenched with triethylamine (8 drops), filtered through Celite®, and washed with additional DCM. The filtrate was concentrated to give the crude glycosylated product as a yellow syrup (15.4 g), which was dissolved in a minimum amount of DCM, and the solution was purified by column chromatography (4 × 22 cm silica) using a gradient solvent of 25 to 35% EtOAc in hexanes to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine conjugate as a colorless syrup (7.95 g, 77%) (R in 35% EtOAc). f 0.4).
[0209] 1H NMR(400MHz,CDCl3)δ8.05-7.99(m,2H),7.98-7.93(m,2H),7.92-7.88(m,2H),7.86-7.79(m,2H),7.59-7.46( m,3H),7.46-7.24(m,9H),5.90(dd,J=9.7,9.7Hz,1H),5.68(dd,J=9.7,9.7Hz,1H),5.52(dd,J=9.7,7.8Hz,1H) ,4.84(d,J=7.8Hz,1H),4.64(dd,J=12.2,3.2Hz,1H),4.49(dd,J=12.2,5.2Hz,1H),4.20-4.13(m,1H),3.95(d dd,J=9.7,5.2,3.2Hz,1H),3.61-3.50(m,1H),3.24-2.99(m,2H),2.66(s,3H),1.82-1.68(m,2H),1.39(s,9H).
[0210] Step 2: To a 500 mL RBF containing 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine conjugate (7.95 g, 10.35 mmol, 1 equiv.) was added DCM (50 mL) and a stir bar. The mixture was stirred briefly (250 rpm) until a solution formed, after which TFA (10 mL) was added. The mixture was stirred for 0.5 h and analyzed by TLC (30% EtOAc / Hexane, R f (starting material) = 0.4, R f (Product) = 0), visualized by UV. The reaction was concentrated by rotary evaporation and then reconcentrated from CHCl (2 × 30 mL) to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylproproxyammonium trifluoroacetate conjugate as a light syrup (11.0 g), which was used without further purification.
[0211] 1H NMR(400MHz,CDCl3)δ8.69(brs,1H),8.15(brs,1H),8.08-8.02(m,2H),7.99-7.88(m,4H),7.87-7.80(m,2H),7.67(br s,1H),7.63-7.48(m,3H),7.52-7.24(m,9H),5.99(dd,J=9.8,9.8Hz,1H),5.71(dd,J=9 .8,9.8Hz,1H),5.38(dd,J=9.8,7.8Hz,1H),4.82(d,J=7.8Hz,1H),4.74(dd,J=12.3,2. 8Hz,1H),4.47(dd,J=12.3,5.0Hz,1H),4.22-4.06(m,2H),3.73(app.p,J=5.1Hz,1H),3 .31-3.18(m,1H),3.14-3.01(m,1H),2.79(t,J=5.3Hz,3H),2.04(app.p,J=5.4Hz,2H).
[0212] Step 3: A 500 mL RBF was charged with a stir bar, phyllochlorin (4.05 g, 7.96 mmol, 1 equiv.), and DCM (60 mL). 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylpropyloxyammonium trifluoroacetate conjugate (6.91 g, 10.35 mmol, 1.3 equiv.) was dissolved in DCM (20 mL) and transferred to the RBF. Triethylamine (6.62 mL, 47.8 mmol, 6 equiv.) was added, followed by PyBOP (4.97 g, 9.55 mmol, 1.2 equiv.), and the mixture was stirred for 0.5 h. TLC analysis indicated consumption of starting material and presence of product (5% MeOH / DCM, R f (phyllochlorin) = 0.25, R f(Product) = 0.95, visualized by UV). The mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 75 mL), then with pH 7 phosphate buffer (100 mL), then dried (NaSO) and concentrated by rotary evaporation to give the crude product as a green film (16.3 g). The crude product was purified by Biotage automated column chromatography (0–2% MeOH / DCM) to give phyllochlorin β-D-glucosyl-N-methylpropylamide conjugate tetrabenzoate as a green film (4.75 g, 52%) (HPLC purity: 95.9%).
[0213] Step 4: To a 500 mL RBF containing phyllochlorin β-D-glucosyl-N-methylpropylamide conjugate tetrabenzoate (4.65 g, 4.01 mmol, 1 equiv.) was added DCM (50 mL), MeOH (50 mL), and a stir bar. The mixture was stirred briefly (300 rpm) until a dark solution formed, whereupon a solution of NaOMe (4.6 M in MeOH, 0.44 mL, 2.01 mmol, 0.5 equiv.) was added and the mixture was stirred for 2 h. TLC analysis at this point indicated complete reaction (10% MeOH / DCM, R f (starting material) = 0.95, R f (Product) = 0). The reaction mixture was concentrated, and the residue was purified by Biotage autocolumn chromatography (5-12% MeOH / DCM) to give compound 15 (2.34 g, 79%) as a blue / green flaky solid (HPLC purity: 99.4%). 1 The H NMR (400 MHz, CD3OD) is shown in Figure 10.
[0214] Synthesis Example 16 - Synthesis of phyllochlorin α-D-1-thiomannose-N-methylpropylamide conjugate (compound 16) [ka] Step 1: To a solution of (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-((3-((tert-butoxycarbonyl)(methyl)amino)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (250 mg, 0.4668 mmol, 1.3 equiv) in DCM (2.3 mL) was added TFA (0.6 mL). The resulting solution was stirred (420 rpm) at ambient temperature for 1 h and then concentrated by rotary evaporation. The residue was resuspended and concentrated twice from chloroform (2 × 3 mL) to give the deprotected amine as a viscous oil, which was dissolved in DCM (1 mL) for the subsequent coupling reaction.
[0215] Step 2: To a 10 mL RBF was added phyllochlorin (182.6 mg, 0.3590 mmol, 1 equiv.), PyBOP (242.9 mg, 0.46678 mmol, 1.3 equiv.), DCM (2 mL), and triethylamine (0.39 mL, 2.5005 mmol, 6 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 15 min, and then a prepared solution of the deprotected amine in DCM was added in one portion. The resulting mixture was stirred for 90 min. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 3 mL) followed by pH 7 buffer (1 × 5 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a foamy blue / black film. The crude product was purified by Biotage autocolumn chromatography (0–5% MeOH / DCM) to give phyllochlorin α-D-l-thiomannose-N-methylpropylamide conjugate peracetate as a blue / black solid (0.16 g, 48%).
[0216] Step 3: To a solution of phyllochlorin α-D-l-thiomannose-N-methylpropylamide conjugate peracetate (0.18 g, 0.1728 mmol, 1 equiv.) in MeOH (2 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 38 μL, 0.1728 mmol, 1 equiv.) was added, and the mixture was stirred (420 rpm) under N for 90 min. The reaction was quenched with AcOH (10.0 μL, 0.1728 mmol, 1 equiv.) and concentrated by rotary evaporation to give a black film. The crude amide was purified by Biotage autocolumn chromatography to give compound 16 as a blue / black solid (71.8 mg, 55%).
[0217] 1 H NMR(400MHz,d6-DMSO)δ9.75(s,1H),9.74(s,1H),9.10(d,J=9.5Hz,1H),9.06(s,1H),8.34(dd,J=17.8,11.6Hz,1H),6.44(dd ,J=17.7,1.6Hz,1H),6.17(dd,J=11.6,1.5Hz,1H),5.15(dd,J=40.4,1.4Hz,1H),5.09-4.37(m,5H),3.98(d,J=6.7Hz,3H),3.8 2(q,J=7.4Hz,2H),3.77-3.64(m,2H),3.64-3.59(m,4H),3.54(d,J=2.2Hz,3H),3.34-3.24(m,4H),2.96-2.91(m,1H),2.88(s, 2H),2.80(s,1H),2.65-2.53(m,1H),2.48-2.33(m,1H),1.90-1.76(m,2H),1.69(t,J=7.6Hz,7H),-2.27(s,1H),-2.43(s,1H).
[0218] Synthesis Example 17 - Synthesis of phyllochlorin β-D-1-thiomannose-N-methylpropylamide conjugate (compound 17) [ka] Step 1: To a solution of (2R,3R,4S,5S,6S)-2-(acetoxymethyl)-6-((3-((tert-butoxycarbonyl)(methyl)amino)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (250 mg, 0.4668 mmol, 1.3 equiv) in DCM (2.3 mL) was added TFA (0.6 mL). The resulting solution was stirred (420 rpm) at ambient temperature for 1 h and then concentrated by rotary evaporation. The residue was resuspended and concentrated twice from chloroform (2 × 3 mL) to give the deprotected amine as a viscous oil, which was dissolved in DCM (1 mL) for the subsequent coupling reaction.
[0219] Step 2: To a 10 mL RBF was added phyllochlorin (182.6 mg, 0.3590 mmol, 1 equiv.), PyBOP (242.9 mg, 0.46678 mmol, 1.3 equiv.), DCM (2 mL), and triethylamine (0.39 mL, 2.5005 mmol, 6 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 15 min, and then a prepared solution of the deprotected amine in DCM was added in one portion. The resulting mixture was stirred for 90 min. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 3 mL) followed by pH 7 buffer (1 × 5 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to yield a foamy blue / black film. The crude product was purified by Biotage autocolumn chromatography (0–5% MeOH / DCM) to give phyllochlorin β-D-1-thiomannose-N-methylpropylamide conjugate peracetate as a blue / black solid (0.18 g, 54%).
[0220] Step 3: To a solution of phyllochlorin β-D-l-thiomannose-N-methylpropylamide conjugate peracetate (0.18 g, 0.1944 mmol, 1 equiv.) in MeOH (2 mL) and DCM (2 mL), NaOMe (4.6 M in MeOH, 43 μL, 0.1944 mmol, 1 equiv.) was added, and the mixture was stirred (420 rpm) under N for 90 min. The reaction was quenched with AcOH (11.1 μL, 0.1944 mmol, 1 equiv.) and concentrated by rotary evaporation to give a black film. The crude amide was purified by Biotage autocolumn chromatography to give compound 17 as a blue / black solid (107.9 mg, 73%).
[0221] 1 H NMR(400MHz,d6-DMSO)δ9.74(s,1H),9.73(s,1H),9.11(d,J=16.9Hz,1H),9.06(s,1H),8.33(dd,J=17.8,11.6Hz,1H),6.4 3(dd,J=17.9,1.6Hz,1H),6.16(dd,J=11.6,1.5Hz,1H),4.88-4.52(m,7H),4.47(dt,J=22.0,5.8Hz,1H),3.98(d,J=5.7Hz, 3H),3.80(q,J=7.8Hz,2H),3.77-3.71(m,1H),3.64-3.58(m,3H),3.54(d,J=3.8Hz,3H),3.32(s,5H),2.89(s,2H),2.78(s, 1H),2.55(q,J=7.6Hz,2H),2.46-2.35(m,1H),1.89-1.75(m,1H),1.75-1.64(m,7H),-2.26(s,1H),-2.42(d,J=2.1Hz,1H).
[0222] Synthesis Example 18 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropanamide (also known as phyllochlorin N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropylamide) (Compound 18) [ka] To a 100 mL RBF equipped with a nitrogen inlet and containing a stir bar was added phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (40 mL), PyBOP (2.46 g, 4.72 mmol, 1.2 equiv.), and triethylamine (0.87 mL, 3 equiv.). The mixture was stirred at room temperature for 30 minutes, and then 2-(2-methylaminoethoxy)ethanol (0.61 g, 1.3 equiv.) in DCM (5 mL) was added in one portion. The mixture was stirred at room temperature overnight. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 50 mL) followed by pH 7 buffer (2 × 50 mL). The organic layer was dried (Na2SO4) and concentrated by rotary evaporation to give the crude product as a blue / green film (4.2 g), which was purified by column chromatography (5 x 25 cm silica) eluting with 1-3% MeOH / DCM. TLC (R in 5% MeOH / DCM) f The pure fractions from 0.40) were combined to give compound 18 (1.40 g, 58%) (HPLC purity: 94.4%).
[0223] 1 H NMR(400MHz,CDCl3)δ9.72(m,2H),8.87-8.82(m,1H),8.16(dd,1H),6.39(dd,1H),6.15(dd,1H),4.7 2-4.65(m,1H),4.59-4.50(m,1H),4.01(s,3H),3.85(q,2H),3.65(s,3H),3.60-3.55(m,2H),3.53(s ,3H),3.41-3.38(m,2H),3.37(s,3H),3.35-3.30(m,2H),2.76-2.71(m,1H),2.65-2.50(m,4H),2.50 -2.40(m,1H),2.38-2.30(m,3H),2.30-2.20(m,2H),1.90-1.80(m,1H),1.80-1.73(m,7H),-2.09(br s,1H),-2.22(br s,1H).
[0224] Synthesis Example 19 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-methyl-N-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propyl)propanamide zinc complex (compound 19) [ka] To a 25 mL single-neck RBF was added phyllochlorin β-D-1-thioglucose-N-methylpropylamide conjugate (50 mg, 0.066 mmol, 1 equiv.) and DCM (2 mL). A solution of zinc acetate (24 mg, 0.132 mmol, 2 equiv.) in methanol (1 mL) was added, and the mixture was stirred under nitrogen in the dark for 2 h. The solution was then diluted with DCM (20 mL), washed with water (3 × 25 mL), dried (NaSO), and concentrated to give compound 19 as a blue solid (54 mg, quantitative) (HPLC purity: 98.5%).
[0225] 1 H NMR(400MHz,CDCl3)δ9.80-9.20(br s,2H),8.70-8.50(br s,2H),8.20-8.00(br s,1H),6.25-5.90(br m,2H),4.50-4.00(br s,2H),4.00-3.20(br m,14H),3.10(br m,2H),2.70-2.10(br m,10H),2.00-1.30(br m,28H),1.20-0.80(br m,5H).
[0226] Synthesis Example 20 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(2-(2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethyl)propanamide (Compound 20) [ka] Step 1: A three-necked 100 mL RBF was charged with (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2-(2-azidoethoxy)ethoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (1.00 g, 2.167 mmol, 1 equiv.), 10% Pd / C (25 mg), methanol (100 mL), and a stir bar. A hydrogen balloon was attached, and the flask was evacuated and refilled with nitrogen (three times), and evacuated and refilled with hydrogen (twice). The resulting solution was then stirred (550 rpm) under a hydrogen atmosphere for 1 hour. The solution was filtered through Celite® (0.5 × 3 cm), washed with DCM (approximately 30 mL), and the solvent was then removed under reduced pressure to give 1.02 g of crude amine product, which was used directly in the next step.
[0227] Step 2: To a 50 mL RBF was added phyllochlorin (0.85 g, 1.67 mmol, 1 equiv.), PyBOP (1.04 g, 2.01 mmol, 1.2 equiv.), DCM (20 mL), and triethylamine (1.39 mL, 10.03 mmol, 6 equiv.). The resulting mixture was stirred (250 rpm) under nitrogen at ambient temperature for 15 minutes, and then the amine (1.02 g) in DCM (5 mL) was added in one portion. The resulting mixture was stirred overnight in the dark under nitrogen. The reaction mixture was diluted with DCM (30 mL), transferred to a separatory funnel, and washed with 1 M HCl (2 × 75 mL) followed by pH 7 buffer (1 × 100 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue / black oil (approximately 2.5 g), which was purified by column chromatography (4 x 25 cm silica) eluting with 1% to 2.5% MeOH / DCM. The product-containing fractions (R in 5% MeOH / DCM) were f Approximately 0.4%) were combined to give phyllochlorin β-D-1-glucose-N-ethoxyethylamide conjugate tetraacetate as a blue / black solid (0.65 g, 42%) (HPLC purity: 83%), which was deprotected without further purification.
[0228] Step 3: To a solution of phyllochlorin β-D-l-glucose-N-ethoxyethylamide conjugate tetraacetate (600 mg, 0.648 mmol, 1 equiv.) in MeOH (7 mL) and DCM (7 mL), NaOMe (4.6 M in MeOH, 0.14 mL, 0.648 mmol, 1 equiv.) was added, and the mixture was stirred (300 rpm) under nitrogen for 90 min. HPLC analysis showed conversion to the deacetylated product. The reaction was quenched with AcOH (19 mg, 0.5 equiv.) and concentrated by rotary evaporation to give a black film, which was purified by column chromatography (4 x 24 cm silica) eluting with 5-12% MeOH / DCM. The R in 10% MeOH / DCM was purified. f Fractions with 0.20 were combined to give compound 20 as a blue / black solid (310 mg, 63%).
[0229] Synthesis Example 21 - Synthesis of 3-((7S,8S)-18-ethyl-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)-N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropanamide zinc complex (Compound 21) [ka] To a 50 mL single-neck RBF was added phyllochlorin N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropylamide (200 mg, 0.328 mmol, 1 equiv.) and DCM (10 mL). A solution of zinc acetate (120 mg, 0.656 mmol, 2 equiv.) in methanol (5 mL) was added, and the mixture was stirred under nitrogen in the dark for 2 h. The solution was then diluted with DCM (20 mL), washed with water (3 × 25 mL), dried (NaSO), and concentrated to give the crude product as a blue solid. The crude product was purified by column chromatography (3 × 18 cm silica) using a 3% MeOH / DCM solvent mixture. The pure fractions (R in 5% MeOH / DCM) were f =0.45) were combined to give compound 21 as a blue flaky solid (203 mg, 92%) (HPLC purity: 93.2%).
[0230] 1 H NMR(400 MHz,CDCl3)δ9.80-9.25(br s,2H),8.80-8.50(br s,2H),8.20-8.00(br s,1H),6.30-6.15(br m,1H),6.10-5.95(br m,1H),4.80-4.10(br m,2H),4.00-3.70(br m,9H),3.70-3.20(br m,14H),2.85-2.60(br m,4H),2.50(br s,3H),2.50-2.30(brm,5H),2.25-2.20(m,5H),1.85-1.60(m,12H),1.50-1.40(m,5H),1.20-1.00(br m,2H).
[0231] Synthesis Example 2: Synthesis of 2-phyllochlorin(6-hexyl)triphenylphosphonium chloride propylamide (Compound 22) [ka] To a 25 mL RBF was added phyllochlorin (100 mg, 0.1966 mmol, 1 equiv.), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium chloride (DMTMM) (76 mg, 0.2752 mmol, 1.4 equiv.), DCM (5 mL), triethylamine (44 μL, 0.3145 mmol, 1.6 equiv.), and (6-aminohexyl)triphenylphosphonium chloride hydrochloride (120 mg, 0.2752 mmol, 1.4 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 min. The reaction mixture was concentrated using a rotary evaporator and the crude residue was purified by column chromatography (silica, 5-7% MeOH / DCM) to give compound 22 as a dark blue / green solid (180 mg, quantitative).
[0232] 1H NMR(400MHz,CDCl3)δ9.67(m,2H),8.89(s,1H),8.78(s,1H),8.14(dd,1H),7.83(t,1H) ),7.62(m,6H),7.48(m,9H),6.35(d,1H),6.10(d,1H),4.70(q,1H),4.51(m,1H),3.98 (m,7H),3.82(q,2H),3.60(s,3H),3.49(m,5H),3.35(s,3H),3.26(m,2H),2.88(m,1H) ,2.61-2.48(m,2H),1.90-1.80(m,1H),1.78-1.70(m,6H),1.60-1.40(m,8H),-2.11(br s,1H),-2.24(br s,1H).
[0233] Synthesis Example 23 - Synthesis of phyllochlorin N-meglumine-propylamide (Compound 23) [ka] To a 50 mL RBF was added phyllochlorin (0.50 g, 0.983 mmol, 1 equiv.), DMTMM (0.30 g, 1.081 mmol, 1.1 equiv.), DCM (15 mL), and meglumine (0.23 g, 1.179 mmol, 1.2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 1 h. Additional meglumine (0.10 g, 0.51 mmol, 0.5 equiv.) was added, and the solution was stirred for an additional 3 h. The reaction mixture was transferred to a separatory funnel, diluted with chloroform (30 mL), and washed with 0.5 M HCl (50 mL). The aqueous layer was re-extracted with chloroform, and the combined organics were washed with pH 7 buffer. The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give a blue / black film. This was purified by column chromatography (silica) using a gradient of 5% MeOH / DCM (50 mL), then 7% MeOH / DCM (100 mL), then 9% MeOH / DCM (100 mL), then 10% MeOH / DCM (200 mL) to give compound 23 as a dark blue / green solid (432 mg, 64%).
[0234] 1H NMR(400MHz,d6-DMSO)δ9.74(s,1H),9.72(s,1H),9.11(s,1H),9.07(s,1H),8.34(dd,1H),6.44(d,1H),6. 17(d,1H),5.10&4.75(2xd,1H),4.65-4.40(m,5H),4.30(m,1H),4.00(m,3H),3.90(m,1H),3.80(m,2H),3. 68(m,1H),3.62(s,3H),3.60-3.50(m,5H),3.50-3.40(m,2H),3.30-3.08(m,1H),3.00(s,1H),2.90(s,2H) ,2.86-2.60(m,1H),2.45-2.35(m,1H),1.75-1.65(m,6H),1.75-1.50(m,1H),-2.26(s,1H),-2.42(s,1H).
[0235] Synthesis Example 24 - Synthesis of phyllochlorin 2-deoxy-D-mannosamine-propylamide (Compound 24) [ka] To a 25 mL RBF containing a stir bar was added phyllochlorin (250 mg, 0.491 mmol, 1 equiv.), DMTMM (127 mg, 0.541 mmol, 1.1 equiv.), DMF (3 mL), triethylamine (75 μL, 0.541 mmol, 1.1 equiv.), and (D)-mannosamine hydrochloride (117 mg, 0.541 mmol, 1.1 equiv.). The resulting mixture was stirred for 30 min. Additional DMTMM (13 mg, 0.1 equiv.), triethylamine (7 μL, 0.1 equiv.), and (D)-mannosamine hydrochloride (10 mg, 0.1 equiv.) were added, and the solution was stirred for an additional 30 min. The reaction mixture was concentrated by rotary evaporation to give a black residue. The residue was taken up in DCM (20 mL) and washed with 0.5 M HCl (10 mL). The DCM layer was collected and washed with pH 7 phosphate buffer. The mixture was extracted with 1:1 DCM / MeOH (3 × 10 mL), dried (NaSO), and concentrated to give a dark solid (approximately 220 mg), which was subjected to column chromatography (silica). The column was eluted using a gradient of 8% MeOH / DCM, then 12% MeOH / DCM, then 14% MeOH / DCM. The fractions containing compound 24 were combined and dried under vacuum to give a dark blue solid (105 mg, 32%).
[0236] 1H NMR(400MHz,d6-DMSO)δ9.76(s,1H),9.74(s,1H),9.05-9.12(m,2H),8.34(dd,1H),7.54&7.18(2xd,1H),6.60-6.42(m,2) H),6.17(d,1H),4.93(m,1H),4.72-4.50(m,4H),4.30-4.20(m,1H),4.01(m,1H),3.95(m,3H),3.82(q,2H),3.80-3.72(m, 1H), 3.65-3.60 (m, 4H), 3.58-3.52 (m, 4H), 3.50-3.40 (m, 2H), 3.17-3.02 (m, 1H), 2.68-2.57 (m, 1H), 2.48-2.38 (m, 1H), 2.25-2.12 (m, 1H), 1.82-1.67 (m, 7H), -2.26 (brs, 1H), -2.43 (brs, 1H). The product exists as a mixture of epimers, giving rise to two sets of signals in an approximately 3:1 ratio.
[0237] Synthesis Example 25 - Synthesis of phyllochlorin 2-deoxy-D-galactosamine-propylamide (Compound 25) [ka] To a 25 mL RBF containing a stir bar was added phyllochlorin (250 mg, 0.491 mmol, 1 equiv.), DMTMM (149 mg, 0.541 mmol, 1.1 equiv.), DMF (3 mL), triethylamine (75 μL, 0.541 mmol, 1.1 equiv.), and (D)-(+)-galactosamine hydrochloride (116 mg, 0.541 mmol, 1.1 equiv.). The resulting mixture was stirred for 30 min, at which point HPLC analysis indicated approximately 4% phyllochlorin remained. Additional DMTMM (14 mg, 0.1 equiv.), triethylamine (7 μL, 0.1 equiv.), and (D)-(+)-galactosamine hydrochloride (11 mg, 0.1 equiv.) were added, and the solution was stirred for an additional 30 min. The reaction mixture was concentrated by rotary evaporation to yield a black residue. The residue was subjected to column chromatography. The column was eluted using a gradient of 10% MeOH / DCM (300 mL), then 15% MeOH / DCM (300 mL), then 20% MeOH / DCM. The product-containing fractions were combined and the solvent was removed by rotary evaporation. The solid was dried under vacuum at 60 °C to give compound 25 (275 mg, 84%) as a dark blue solid.
[0238] 1 H NMR(400MHz,d6-DMSO)δ9.74(d,J=6.2Hz,2H),9.13-8.95(m,2H),8.33(dd,J=17.8,11.6Hz,1H),7.66(dd,J =36.3,8.5Hz,1H),6.50-6.33(m,1H),6.27-6.07(m,2H),4.92(t,J=3.9Hz,1H),4.72-4.22(m,5H),4.00-3.9 0 (m, 3H), 3.88-3.67 (m, 4H), 3.62 (d, J = 0.9 Hz, 4H), 3.55 (s, 4H), 3.33 (s, 24H), 2.53-2.47 (m, 4H), 2.20-1.99 (m, 1H), 1.84-1.62 (m, 8H), -2.25 (s, 1H), -2.41 (s, 1H). The product exists as a mixture of epimers, giving rise to two sets of signals in an approximately 3:1 ratio. [Example]
[0239] Biological experiment details Example 1 - Determination of the solubility of phyllochlorin analogues The absorbance maximum (660 ± 2 nm for phyllochlorin) was used as a surrogate measure of solubility. Related phyllochlorin analogues were diluted to 50 μM in PBS (phosphate-buffered saline) solution, containing a decreasing amount of DMSO from 100% to 0%.
[0240] PBS buffer (pH 7.4) was used in the experiments, and since the pKa of the carboxylic acid of phyllochlorin (and the same carboxy group of other related chlorins) is estimated to be less than 5, phyllochlorin in PBS buffer exists primarily as the sodium and potassium salts with little or no free acid.
[0241] Where necessary, polyvinylpyrrolidone (K30) was added to a final concentration of 1% w / v. Absorbance was measured using a Cytation 3 multimode plate reader (Biotek) in spectral scanning mode. Spectra were captured between 500 and 800 nm in 2 nm increments. An equivalent volume of blank solution was also measured and subtracted accordingly. Each spectrum was normalized to have a minimum signal of 0 and a maximum signal of 100% pure DMSO solution (the most soluble state).
[0242] Results - Phyllochlorin solubility and absorbance maximum The solubility of phyllochlorin was evaluated in solutions containing DMSO as the organic solvent. Phyllochlorin (final concentration 50 μM) was resuspended in 100% DMSO to completely dissolve the phyllochlorin. While maintaining the phyllochlorin concentration at 50 μM, the DMSO percentage was gradually decreased from 100% to 0%. All solutions were vortexed and then centrifuged for 2 minutes to pellet insoluble material. 150 μl aliquots were transferred to individual wells of a 96-well clear microplate, and absorption spectra were collected from 500 to 800 nm in 2 nm increments. Equivalent volumes of solutions containing decreasing DMSO percentages were used to control for background.
[0243] In aqueous solvents, phyllochlorin exhibited a single broad absorbance peak with a maximum at 688 ± 2 nm, which resolved into two distinct peaks with maxima at 688 and 660 ± 2 nm, respectively (Figure 1). The absorbance peak at 688 nm decreased with increasing DMSO concentration, and at 75% DMSO, only a single absorbance maximum was observed at 660 ± 2 nm. Thus, the solubility of phyllochlorin depended on the organic solvent concentration. When completely solubilized in organic solvent, the absorbance maximum was 660 ± 2 nm.
[0244] Results: The addition of PVP improved the solubility of phyllochlorin. To improve the solubility of phyllochlorin, the addition of 1% w / v PVP was tested. PVP significantly increased the solubility, and phyllochlorin remained soluble in aqueous solvent (without DMSO) in the presence of 1% PVP. Furthermore, the absorbance peak of phyllochlorin at 688 nm was absent when PVP was introduced. This indicates that the solubility of phyllochlorin was improved in the presence of PVP (Figure 2).
[0245] Results - Solubility and absorbance maxima of phyllochlorin analogues The absorbance spectra of several phyllochlorin analogs (compounds 1-3) were measured in the presence of 1% PVP (w / v) as previously described. The majority of the phyllochlorin analogs tested had an absorbance maximum at 660 ± 2 nm, as previously measured in the presence of 1% PVP (w / v).
[0246] Example 2 - Cytotoxicity, Phototoxicity and Therapeutic Index Preparation of chlorin stock solution Photosensitizers (e.g., phyllochlorin, phyllochlorin analogs, chlorin e4 disodium (provided by Advanced Molecular Technologies, Scoresby) or talaporfin sodium (purchased from Focus Bioscience, catalog number HY-16477-5MG)) were resuspended in 100% dimethyl sulfoxide (DMSO) at a concentration of 5.5 mM. Samples were stored at 4°C, protected from light.
[0247] cell culture The human ovarian cancer cell line SKOV3 (ATCC #HTB-77) was maintained in Dulbecco's modified Eagle's medium / nutrient mixture F-12 (DMEM / F-12) supplemented with 10% (v / v) fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Monolayer cultures were grown in a humidified incubator at 37°C with 5% CO.
[0248] Preparation of chlorins for in vitro experiments For in vitro experiments, photosensitizers (5.5 mM stock solutions in 100% DMSO) were diluted in cell culture medium (Dulbecco's modified Eagle's medium / nutrient mixture F-12) supplemented with 10% (v / v) fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and 10% (w / v) Kollidon-12. When cells reached approximately 80% confluence, the spent medium was replaced with medium containing the photosensitizer, and the cells were incubated for the required time to allow for uptake of the photosensitizer.
[0249] statistical analysis All data were analyzed using GraphPad PRISM v8.3.1(549) (GraphPad Software, CA). Spectral absorbance and viability measurements were normalized to a range of 0–100%, with the minimum value at 0 and the maximum value determined from the data set. Dose-response was determined using sigmoidal four-point nonlinear regression with variable slope, and IC50 values were calculated for each compound. All data are presented as mean ± SD (where applicable).
[0250] cytotoxicity SKOV3 cells were seeded into 96-well black-wall plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0–100 μM of the relevant phyllochlorin analogue in DMSO. Cells were incubated for an additional 24 h to allow for uptake of the phyllochlorin analogue.
[0251] To test the intrinsic cytotoxicity (i.e., "dark toxicity") of phyllochlorin analogs, the medium was replaced with fresh medium containing 10% (v / v) AlamarBlue cell viability reagent (ThermoFisher) after 24 hours, and the cells were incubated at 37°C for 6 hours. Untreated cells were used as a control. Fluorescence (Ex 555 nm / Em 596 nm) was measured using a Cytation3 multimode plate reader (Biotek), and cytotoxicity was assessed according to the percentage of viable cells remaining. All measurements were performed in quadruplicate.
[0252] Results - Cytotoxicity of phyllochlorin compared to chlorin e4 disodium To assess the intrinsic cytotoxicity of phyllochlorin (i.e., "dark toxicity"), SKOV3 ovarian cancer cells were incubated with phyllochlorin concentrations ranging from 0 to 100 µM (in DMSO) for 24 h. Cell viability was assessed using AlamarBlue cell viability reagent and compared to untreated controls. Measurements were performed using phyllochlorin both in the presence or absence of PVP.
[0253] In the absence of PVP, cells treated with chlorin e4 disodium at concentrations up to 80 μM maintained >80% viability after 24 hours. With the addition of PVP, viability was maintained at 100 μM. Cells treated with phyllochlorin in the absence of PVP maintained >80% viability even at 10 μM. However, with the addition of PVP, cells maintained less than 80% viability at concentrations up to 25 μM (Figure 3). Thus, the addition of PVP reduced the inherent toxicity of both compounds and improved cellular tolerance to phyllochlorin by increasing their solubility.
[0254] Surprisingly, phyllochlorin with PVP added has lower dark toxicity and a higher therapeutic index than phyllochlorin without PVP added.
[0255] phototoxicity SKOV3 cells were seeded into 96-well black-wall plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0–100 μM of the relevant phyllochlorin analogue in DMSO. Cells were incubated for an additional 24 h to allow for uptake of the phyllochlorin analogue.
[0256] To test for phototoxicity, cells incubated with phyllochlorin analogues (0–10 μM in DMSO) were exposed to 50 mW / cm light after 24 h with a medium change (as above) and then to 50 mW / cm light. 2 The specimen was exposed to a 652 nm laser (Invion) for 5 min at a laser density of 15 J / cm2 (total). 2 After activation, cells were cultured for an additional 24 hours. The medium was then replaced with fresh medium containing AlamarBlue, and the survival rate of viable cells was assessed as described above. Controls included cells treated with phyllochlorin analogs but not activated by laser light, cells not treated with phyllochlorin analogs but irradiated with laser light, and an untreated control. All measurements were performed in quadruplicate.
[0257] For comparative purposes, phyllochlorin analogs were tested and compared with both chlorin e4 disodium and talaporfin sodium, a clinically approved photosensitizer used in the photodynamic therapy of lung cancer. Phototoxicity and dark toxicity IC values were calculated using a normalized dose-response curve with varying slope using the equation log[inhibitor] vs. Hill slope (phototoxicity IC), or Y = 100 / (1 + (IC / X)^ Hill slope (dark toxicity IC).
[0258] Results - Phototoxicity of phyllochlorin compared to chlorin e4 disodium To assess phototoxicity, cells were treated with increasing concentrations of phyllochlorin or chlorin e4 disodium (0–10 μM in DMSO, prepared in the presence or absence of PVP) followed by laser (652 nm) activation. Chlorin e4 disodium was included to assess their comparative efficacy. In each case, IC50 values were estimated from fitted curves. In the absence of PVP, chlorin e4 disodium returned an IC50 of 4.53 μM. This was improved by adding PVP to 1.35 μM. In contrast, the calculated IC50 for phyllochlorin was 63.07 nM. Adding PVP reduced this to 53.85 nM (Figure 4).
[0259] Surprisingly, phyllochlorin was approximately 75 times more potent as a phototoxicant than chlorin e4 disodium salt (0.06 μM to 4.53 μM) in a head-to-head study on ovarian cancer cells. Thus, phyllochlorin exhibits substantially greater phototoxicity than chlorin e4 disodium in vitro.
[0260] Toxicity profiles of phyllochlorin analogues The phototoxicity and intrinsic cytotoxicity (i.e., "dark toxicity") of several phyllochlorin analogs were previously evaluated using SKOV3 ovarian cancer cells. For comparative purposes, phyllochlorin analogs were compared to chlorin e4 disodium and talaporfin sodium, a clinically approved photosensitizer used in the photodynamic therapy of lung cancer. Phototoxicity IC90 and dark toxicity IC10 values were calculated using a normalized dose-response curve with a slope varying using the equation log[inhibitor] vs. Hill slope (phototoxicity IC90), or Y = 100 / (1 + (IC10 / X)^ Hill slope (dark toxicity IC10). The results are summarized in Table 1.
[0261] Both phyllochlorin and phyllochlorin monosodium salt (compound 1) exhibited similar phototoxicity and dark toxicity profiles, as expected for conversion of the free acid to its salt form in the sodium carbonate buffer system used in cell culture. Chlorin E4 disodium and talaporfin sodium were significantly less phototoxic in vitro than all phyllochlorin analogs tested, with IC90 values in the μM range (versus the nM range for phyllochlorin analogs). Compounds 3, 5, 6, 7, and 8 possessed greater phototoxicity than all other species tested, with apparent IC90 values <100 nM in each case. Thus, the phyllochlorin analog species exhibited approximately 450-fold increased phototoxicity compared to talaporfin sodium, a clinically approved photosensitizer.
[0262] Therapeutic index of phyllochlorin analogues To evaluate the therapeutic potential of phyllochlorin analogs, the therapeutic index (TI) was calculated for each compound tested. TI provides a quantitative measure that describes relative drug safety by comparing the drug concentration required for the desired effect with the concentration that results in undesired off-target toxicity. The TI for each case was calculated using the phototoxicity IC90 versus the dark toxicity IC10.
[0263] The TI values of all tested compounds are shown in Table 1. Talaporfin sodium had the lowest calculated therapeutic index (TI = 0.49), while chlorin e4 disodium was slightly superior (TI = 1.89), indicating a smaller usable therapeutic window. The phyllochlorin analogs of the present invention had a relatively improved TI with substantially greater phototoxicity (Table 1).
[0264] Therefore, phyllochlorin analogs have a desirable therapeutic index superior to that of clinically applied photosensitizers. Furthermore, the greater phototoxicity of phyllochlorin analogs suggests the possibility of using significantly reduced doses in vivo. Therefore, phyllochlorin analogs have a therapeutic profile suitable for clinical application. [Table 1-1] [Table 1-2] [Table 1-3]
[0265] Spectral properties of phyllochlorin analogues All prepared phyllochlorin analogs showed four absorption peaks with the Soret band at 404±4 nm and the Q bands in the green, red, and far-red, respectively. Chlorin e4 disodium and talaporfin sodium had similar spectral properties. Zn 2+ Upon complexation with ions (compounds 19 and 21), the spectrum was compressed, the Soret and Q1 bands were red-shifted, and the Q2 and Q3 bands were blue-shifted.
[0266] Phyllochlorin analogues are superior to chlorin e4 disodium and clinically approved talaporfin sodium as photosensitizers Singlet oxygen ( 1 The O2 production, cellular phototoxicity, and light-independent cytotoxicity ("dark toxicity") were compared with chlorin e4 disodium and talaporfin sodium (mono-L-aspartyl chlorin e6), the active ingredient in Laserphyrin™.
[0267] All phyllochlorin analogs showed a significant improvement in efficacy against SKOV3 cancer cells compared to both chlorin e4 disodium and talaporfin sodium. 1 The results showed that O2 production rate and phototoxicity were similarly or significantly enhanced (Table 1). The exception to this rule was Zn 2+ This occurred when compound 19 and compound 21 formed complexes with phyllochlorin analogues, resulting in reduced ROS.
[0268] In some cases, the rate of ROS generation was more than twice that of either comparator (e.g., compound 5). Also, several compounds (e.g., compounds 3, 5, 6, 7, and 8) achieved cellular phototoxicity at less than 100 nM (Table 1). The nonspecific cytotoxicity IC10 was equal to or greater than that of talaporfin sodium in all cases, suggesting that phyllochlorin analogs offer an improved therapeutic profile for use.
[0269] Thus, phyllochlorin analogs are superior to both chlorin e4 disodium and the clinically approved photosensitizer talaporfin sodium, with (i) higher rates of singlet oxygen production, (ii) significantly higher phototoxicity towards cancer cells, and (iii) similar or reduced nonspecific cytotoxicity, suggesting that phyllochlorin analogs should have fewer off-target effects in therapeutic applications.
[0270] Metal ions alter the spectral properties and activity of phyllochlorin analogues Compound 18 was treated with Zn 2+ ions to form compound 21, and their activities were compared. 2+ Upon complexation with Zn, the spectral properties of compound 18 changed, with a clear red shift of 14–16 nm in the Soret and Q1 bands. In contrast, the Q3 and Q4 bands were blue shifted by 8 and 22 nm, respectively. 2+ The inclusion of ions reduced the rate of ROS generation by approximately 2.5-fold, increased nonspecific dark toxicity, and significantly lost phototoxic activity (Table 1).
[0271] Therefore, metal ions have a significant effect on the activity and spectral properties of phyllochlorins and can be used to adjust the activity as needed.
[0272] Functionalization with saccharidiyl groups enhances phototoxicity Phyllochlorin was functionalized with saccharidiyl groups (glucose or mannose) using various configurations to give glucose-linked species (e.g., Compound 6 and Compound 8) and mannose-linked species (e.g., Compound 17). 1 Although the O2 production rates were similar in all species, there was a significant increase in the cellular phototoxicity of each saccharidiyl-conjugated phyllochlorin analog compared to compound 2 (Table 1). In particular, compounds 6 and 8 achieved a significant cellular phototoxicity IC90 of 0.06 μM, an approximately four-fold increase compared to compound 2 (Table 1).
[0273] Example 3 - Cellular uptake and retention Salt substitution does not alter cellular uptake or retention in vitro Based on the increased phototoxicity of compound 1c relative to compound 1, we assessed whether this salt substitution altered cellular uptake or retention over time.
[0274] SKOV3 cells were incubated (as described above) in the presence of either compound 1 or compound 1c for up to 24 hours. At defined time intervals (Figure 5), the medium was aspirated and replaced with sterile PBS, and cell fluorescence (Ex 405 nm / Em 660 nm) was imaged using a Cytation 3 multimode plate reader (Biotek). After 24 hours, the medium was aspirated and replaced with fresh medium, and loss of cell fluorescence was similarly monitored. All images (a minimum of 100 cells per time point) were then quantitatively analyzed (Gen5.0 software) to determine the mean fluorescence / cell / time point. Mean fluorescence measurements were normalized to the maximum mean value measured for each photosensitizer and plotted as percent total fluorescence (mean ± SD) over time.
[0275] The relative uptake of Compound 1 and Compound 1c and their clearance from cells over 24 h are shown in Figure 5. There was no significant difference in uptake or clearance between the two salt forms (Figure 5A), nor was there any apparent difference in cellular localization in either case (Figure 5B), suggesting that choline substitution did not affect cellular affinity or uptake of phyllochlorin.
[0276] Therefore, salt substitution of phyllochlorin can alter its activity against cancer cells. In particular, the phyllochlorin choline salt (compound 1c) showed unexpectedly improved performance compared to other salts, despite no apparent changes in ROS production rate or cellular uptake.
[0277] Compound 2 exhibits prolonged cell retention The uptake and retention of Compound 1 and Compound 2 were compared in SKOV3 cancer cells over a 48-hour period. SKOV3 cells were incubated (as described above) in the presence of either Compound 1 or Compound 2 for up to 24 hours. At defined time intervals (Figure 6), the medium was aspirated and replaced with sterile PBS, and the cells were imaged for fluorescence (Ex 405 nm / Em 660 nm) using a Cytation 3 multimode plate reader (Biotek). After 24 hours, the medium was aspirated and replaced with fresh medium, and loss of cell fluorescence was similarly monitored. All images (minimum 100 cells per time point) were then quantitatively analyzed (Gen5.0 software) to determine the mean fluorescence / cell / time point. Mean fluorescence measurements were normalized to the maximum mean value measured for each photosensitizer and plotted as percent total fluorescence (mean ± SD) over time.
[0278] The relative uptake of Compound 1 and Compound 2 and their clearance from cells over 24 hours are shown in Figure 6. There was no significant difference in the uptake rate between the two compounds. However, Compound 2 was retained at significantly higher levels within cells after 24 hours compared to Compound 1, which lost 80% of its fluorescence within 4 hours. In contrast, after 24 hours, more than 50% of Compound 2 remained intracellularly (Figure 6). Compound 2 also showed a distinct punctate distribution within cells, suggesting a vesicular localization distinct from that of Compound 1 (Figure 6B).
[0279] Functionalization with saccharidiyl groups enhances cellular uptake Phyllochlorin was functionalized with saccharidiyl groups (glucose or mannose) using various configurations, and the effect on cellular uptake rate was assessed over a 4-hour incubation period as described above. The uptake rate of saccharidiyl-conjugated phyllochlorin analogs exceeded that of unconjugated compound 2 (illustrated in Figure 7). After 2 hours, saccharidiyl-conjugated phyllochlorin analogs (compounds 6, 8, and 17) reached 57–68% of maximum uptake compared to 37% for compound 2 (Figure 7A). By 4 hours, total uptake was similar, and there was no apparent difference in cellular distribution between the glucose (compounds 6 and 8) and mannose (compound 17)-conjugated species (Figure 7B). Notably, functionalization also increased relative solubility, resulting in a diffusion distribution pattern more similar to compound 1 than to compound 2 (Figure 7B).
[0280] Example 4 - Phyllochlorin analogues are effective against multiple cancer cell types The activity of phyllochlorin analogs against multiple cancer cell types was evaluated as described above, using compounds 3 and 6 as examples. Phototoxicity is shown in Table 2. Compounds 3 and 6 exhibited exceptional activity against multiple cancer cell types, in some cases with phototoxicity IC90s as low as 0.03 μM (Table 2). These data indicate the potential use of phyllochlorin analogs for pan-cancer therapy. [Table 2]
[0281] Example 5 - Phyllochlorin analogs are non-toxic and localize to tumor tissue in vivo The potential use of compound 6 as a representative phyllochlorin species was investigated in vivo. Wild-type mice (Balb / C and C57BL / 6) were administered compound 6 by intravenous or intraperitoneal injection at doses ranging from 0.5 to 5 mg / kg. No adverse toxic events were observed at any dose, indicating a favorable safety profile consistent with the in vitro data.
[0282] Tumor localization and retention were investigated using two models.
[0283] Model 1 is 10 4 Balb / C wild-type mice were used, subcutaneously implanted with ×4T1 mouse breast cancer cells. When tumors reached a palpable size (approximately 3-6 mm in diameter), mice were administered compound 6 by either oral gavage (oral: 2.5 mg / kg), intravenous injection (IV: 1.0 mg / kg), or intratumoral injection (IT: 1.0 mg / kg in 50 μl). To establish the localization of compound 6, mice were imaged using an IVIS Lumina III In Vivo Imaging System (Perkin Elmer), detecting fluorescence at 660 nm when illuminated under blue (400-460 nm) light.
[0284] Model 2 is 1 x 10 6 C57BL / 6 wild-type mice were intraperitoneally implanted with ID8 mouse ovarian cancer cells. After 4 weeks of incubation (at which point metastatic peritoneal disease with macroscopic tumor deposits was established), mice were administered Compound 6 via oral gavage (oral: 2.5 mg / kg), intravenous injection (IV: 1.0 mg / kg), or intraperitoneal injection (IP: 1.0 mg / kg). Quantitative imaging was performed as described above. However, due to the disseminated nature of ovarian cancer, imaging was performed at autopsy using blue light (400 nm) illumination to visualize the red fluorescence associated with Compound 6 in tumor deposits.
[0285] In all cases, compound 6 was specifically retained in tumor tissue for at least 24 hours after administration. Clearance from healthy tissue was typically achieved within 4–16 hours, depending on the tissue type. The timing and accumulation varied depending on the model and route of administration:
[0286] Oral administration: In primary subcutaneous tumors (Model 1), peak levels of compound 6 occurred 4 hours after administration and remained above background for at least 24 hours (Figure 8A). A similar pattern was observed in metastatic peritoneal tumors (Model 2) (Figure 8A).
[0287] IV administration: In primary subcutaneous tumors (Model 1), compound 6 was detected immediately after injection and peaked 1 hour after administration (Figure 8A). Fluorescence persisted for at least 4 hours after administration and was undetectable 24 hours after injection. In metastatic peritoneal tumors (Model 2), tumor distribution peaked 4 hours after injection. Compound 6 persisted for at least 24 hours after injection (Figure 8A).
[0288] Intratumoral administration (Model 1 only): IT delivery of compound 6 directly into tumor tissue resulted in robust localization and retention in tumor tissue for at least 48 hours (Figure 8A).
[0289] Intraperitoneal administration (Model 2 only): IP administration rapidly and highly selectively localized compound 6 to metastatic nodules in vivo (FIG. 8A).
[0290] The fluorescence of compound 6 was also readily imaged under blue light and was visible to the naked eye (Figure 8B). At autopsy, the primary tumor was visualized as a bright red mass (Figure 8B, left). In mice with metastatic disease, multiple deposits were seen on the peritoneal surface, particularly in the liver, diaphragm, intestine, and extending into adjacent peritoneal masses consistent with ovarian cancer (Figure 8B, right).
[0291] In a second experiment, the localization of compound 6 24 hours after administration was compared with that of talaporfin sodium and 5-aminolevulinic acid (5-ALA), with all compounds injected IT at 0.1 mg / kg. Fluorescence measurements were performed using an IVIS Lumina III instrument (described above). Compound 6 was strongly localized to the tumor, with no apparent involvement of surrounding non-tumor tissue (Figure 8C). In contrast, neither talaporfin sodium nor 5-ALA could be accurately detected at 24 hours. In both cases, a diffuse, non-localized distribution pattern was evident, particularly in the case of 5-ALA (Figure 8C).
[0292] Thus, compound 6 specifically localized and retained in tumor tissue and could be administered via multiple clinically relevant routes. The localization of compound 6 was ostensibly superior to comparable photosensitizers already in clinical use. Furthermore, the inherent fluorescence of compound 6 when illuminated under blue light could be used to more precisely identify or define tumor deposits and cancerous tissue margins in situ.
[0293] Example 6 - Phyllochlorin analogs regress established tumor deposits in vivo Balb / C wild-type mice bearing established 4T1 orthotopically implanted breast tumors were administered Compound 6 by IT injection. 24 hours after injection (to allow Compound 6 to clear from non-tumor tissue), the mice were placed in clear Perspex cages and irradiated (whole body) with red (660 nm) light for 20 minutes. The light (660 nm) was 100 mW / cm. 2 The total light intensity was 120 J / cm for 20 minutes. 2 Tumor size and appearance were then monitored for a total of 2 weeks.
[0294] In mice treated with compound 6 alone, tumors grew rapidly, reaching the endpoint within 13 days (Figure 9). In contrast, in mice treated with compound 6 and laser, tumors regressed to undetectable levels after 14 days (Figure 9). There was no evidence of regrowth even after 3 weeks (not shown), and no visible scarring after treatment (Figure 9, right).
[0295] Thus, compound 6 is an effective photosensitizer for use in photodynamic therapy, resulting in complete tumor regression without evidence of tissue damage scarring.
[0296] Example 7 - Phyllochlorin is non-toxic when injected into mice To assess acute toxicity, phyllochlorin or chlorin e4 disodium (each prepared in 1% PVP + 20 mM HEPES in PBS) was administered at a dose of 5 mg / kg via intraperitoneal injection to C57BL / 6 mice.
[0297] PBS buffer (pH 7.4) was used in the experiments, and since the pKa of the carboxylic acid of phyllochlorin (and the same carboxy group of other related chlorins) is estimated to be less than 5, phyllochlorin in PBS buffer exists primarily as sodium and potassium salts with little or no free acid.
[0298] Mice were observed for 30 minutes for clinical signs of acute toxicity (e.g., strabismus, piloerection, loss of mobility, and general behavior). No adverse effects were observed with either compound, suggesting that phyllochlorin delivered at a dose of 5 mg / kg is safe for injection.
[0299] It will be understood that the invention has been described above by way of example only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope and spirit of the invention, which is defined solely by the claims that follow.
Claims
1. A compound of formula (I) or a complex of formula (II) 【Chemistry 1】 During the ceremony, -R 1 is -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 3 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S (O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y or -R α - [R 6 ]Y; -R α - is independently C 1 ~C 12 alkylene groups, wherein said alkylene groups are optionally selected from one or more C 1 ~C 4 Alkyl, C 1 ~C 4 may be optionally substituted with a haloalkyl or halo group, and one or more carbon atoms in the backbone of said alkylene group may be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, said hydrocarbyl group may be optionally substituted, and said hydrocarbyl group may optionally include one or more heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, halo, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 ~C 6 heteroaryl, wherein said phenyl or C 5 ~C 6 Heteroaryl optionally includes one or more C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, —O(C 1 ~C 4 alkyl), -O(C 1 ~C 4 haloalkyl), halo, -O-(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group; -R 6 Optionally, one or more C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, —O(C 1 ~C 4 alkyl), -O(C 1 ~C 4 haloalkyl), halo, -O-(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC substituted with a group 5 H 5 ]; n is 1, 2, 3 or 4; Y is a counter ion; X is a halo group; M 2+ is a metal ion; a compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof, However, the compound is (1) phyllochlorin free acid; or (2) A compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof, provided that it is not phyllochlorin methyl ester.
2. A compound of formula (I) or a complex of formula (II) 【Chemistry 2】 During the ceremony, -R 1 is -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 3 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S (O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y or -R α - [R 6 ]Y; -R α - is independently C 1 ~C 12 alkylene groups, wherein said alkylene groups are optionally selected from one or more C 1 ~C 4 Alkyl, C 1 ~C 4 may be optionally substituted with a haloalkyl or halo group, and one or more carbon atoms in the backbone of said alkylene group may be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, which may optionally be substituted, and which may optionally include one or more heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, halo, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 ~C 6 heteroaryl, wherein said phenyl or C 5 ~C 6 Heteroaryl optionally includes one or more C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, —O(C 1 ~C 4 alkyl), -O(C 1 ~C 4 haloalkyl), halo, -O-(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group; -R 6 Optionally, one or more C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, —O(C 1 ~C 4 alkyl), -O(C 1 ~C 4 haloalkyl), halo, -O-(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC substituted with a group 5 H 5 ]; n is 1, 2, 3 or 4; Y is a counter ion; X is a halo group; M 2+ is a metal ion; a compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof, 2. A compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof, for use in medicine.
3. Each -R α - is independently C 1 ~C 6 3. The compound or complex according to claim 1 or 2, selected from alkylene.
4. At least one -R 3 is -R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β The compound or complex according to any one of claims 1 to 3, wherein is a saccharidiyl group.
5. -R β teeth, 【Chemistry 3】 5. The compound or complex of claim 4, wherein the saccharidiyl group is selected from:
6. The saccharidiyl group is 【Chemistry 4】 6. The compound or complex of claim 5,
7. -R β teeth, 【Chemistry 5】 is a saccharidiyl group selected from In the formula, -R 7 is C 1 ~C 4 5. The compound or complex of claim 4, wherein the alkyl is selected from the group consisting of alkyl, aryl, aryl and alkyl.
8. The compound or complex of claim 7, wherein R 7 is methyl.
9. -R 1 is -C(O)-N(R 3 ) 2 The compound or complex according to any one of claims 1 to 8,
10. -R 1 is -C(O)-N(R 3 ) (R 3’ ) and -R 3 is -R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β is a saccharidiyl group, -R 3’ is H or C 1 ~C 4 10. The compound or complex of claim 9, which is alkyl.
11. The compound or the complex is 【Chemistry 6-1】 【Chemistry 6-2】 【Chemistry 6-3】 【Chemistry 6-4】 【Chemistry 6-5】 【Chemistry 6-6】 【Chemistry 6-7】 【Chemistry 6-8】 【Chemistry 6-9】 【Chemistry 6-10】 or a complex or a pharma- ceutically acceptable salt thereof.
12. 3. A compound or complex according to claim 1 or 2, wherein the compound is phyllochlorin in the form of a pharma- ceutically acceptable salt.
13. 13. The compound or complex of claim 12, wherein the compound is phyllochlorin sodium, potassium, lithium, choline, arginine or meglumine.
14. The compound is (1) phyllochlorin free acid; or (2) The compound or complex according to claim 2, which is phyllochlorin methyl ester. (a) for use in photodynamic therapy or cytoluminescence therapy; and / or (b) atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell and / or for the treatment of diseases characterized by areas of hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestines, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. (c) for the treatment of diseases characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization, and / or (d) for the treatment of benign or malignant tumors, and / or (e) for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas; and / or (f) A compound or complex according to any one of claims 1 to 14 for use in photodynamic diagnosis.
16. The compound or complex according to any one of claims 1 to 15, wherein the compound is adapted to be administered prior to the administration of radiation.
17. 17. The compound or complex of claim 16, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
18. A pharmaceutical composition comprising a compound or complex according to any one of claims 1 to 17 and a pharma- ceutically acceptable carrier or diluent. (a) polyvinylpyrrolidone, and / or (b) an immune checkpoint inhibitor, and / or (c) an immune checkpoint inhibitor selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab; 20. The pharmaceutical composition of claim 18, further comprising: (a) for use in photodynamic therapy or cytoluminescence therapy; and / or (b) atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell and / or for the treatment of diseases characterized by areas of hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestines, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. (c) for the treatment of diseases characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization, and / or (d) for the treatment of benign or malignant tumors, and / or (e) for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas; and / or (f) A pharmaceutical composition according to claim 18 or 19 for use in photodynamic diagnosis.
21. The pharmaceutical composition comprises: (a) adapted for administration prior to the administration of radiation; and / or (b) adapted for administration prior to administration of electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm; and / or (c) in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumor, intraarticular, intraperitoneal, intracranial and epidural), transdermal, respiratory (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration; and / or (d) The pharmaceutical composition according to any one of claims 18 to 20, which is in a form suitable for oral or parenteral administration.
22. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; by areas of benign or malignant cell hyperproliferation or angiogenesis.
20. Use of a compound or complex according to any one of claims 1 to 17 in the manufacture of a medicament for the treatment of a disease characterized by; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
23. 20. Use of a compound or complex according to any one of claims 1 to 17 in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy.
24. The phototherapy agent may be used to treat a variety of conditions, including but not limited to atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; hyperplasia of benign or malignant cells.
24. The use according to claim 23, for the treatment of a disease characterized by areas of hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
25. The use according to any one of claims 22 to 24, wherein said medicament or said phototherapeutic agent is for the treatment of a disease characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.
26. The use according to any one of claims 22 to 25, wherein the medicament or phototherapeutic agent is for the treatment of a benign or malignant tumor.
27. 27. The use according to any one of claims 22 to 26, wherein the medicament or phototherapy agent is for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
28. 20. Use of a compound or complex according to any one of claims 1 to 17 in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.
29. The use according to any one of claims 22 to 28, wherein the medicament, the phototherapeutic agent or the photodiagnostic agent is adapted for administration prior to the administration of radiation.
30. The use according to claim 29, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
31. (a) a compound or complex according to any one of claims 1 to 17; (b) an immune checkpoint inhibitor,
32. 32. The pharmaceutical combination of claim 31 , wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.
